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Advisory Professor: Nicholas Navin, Ph.D.
Triple-negative breast cancer (TNBC) is an aggressive subtype that displays extensive intratumor
heterogeneity and frequently (46%) develops resistance to neoadjuvant chemotherapy (NAC). Currently, the
genomic basis of chemoresistance remains poorly understood. An important question is whether resistance
to chemotherapy is driven by the selection of rare pre-existing subclones with genomic mutations and
transcriptional programs that confer resistance to chemotherapy (adaptive resistance) or by the spontaneous
induction of new mutations and expression changes that confer a resistant phenotype (acquired resistance).
To investigate this question we applied single cell DNA and RNA sequencing methods and deep-exome
sequencing to longitudinal time-point samples collected from a cohort of 20 TNBC patients. Deep-exome
sequencing of the cohort at three time points revealed patterns of both clonal extinction and clonal
persistence, with a subset of patients displaying adaptive selection of pre-existing rare mutations. Single-cell
copy number profiling of 900 cells from 8 patients also identified an adaptive resistance model, wherein
minor subclones from the pre-treatment tumors were selected and expanded in response to NAC. In
contrast, single cell RNA sequencing of 6,862 cells from 8 patients identified subclones with chemoresistant
phenotypes that were reprogrammed in response to NAC. These data suggest that chemoresistance at the
genotypic level evolves through the selection of pre-existing point mutations and copy number changes,
while chemoresistance at the phenotypic level evolves through the reprogramming of expression changes in
signaling pathways associated with chemoresistance. These characterizations of adaptive and acquired
resistance shed light on the evolutionary trajectory of chemoresistance in TNBC patients.
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CHAPTER 1: INTRODUCTION
1.1 Triple-Negative Breast Cancer
Breast cancer is the most common invasive malignancy in women in the United States, with a high
annual incidence and mortality rate(1, 2). Clinical categorizations of breast cancer rely primarily on
estrogen receptor (ER) and progesterone receptor (PR) protein levels, as determined by
immunohistochemistry (IHC), and human epidermal growth factor receptor 2 (HER2) levels, as
determined by IHC and/or fluorescence in situ hybridization (FISH)(3). Triple-negative breast
cancer (TNBC) – an ER negative, PR negative, and HER2 overexpression negative subtype of breast
cancer – is particularly aggressive, has a higher rate of visceral metastases(4, 5), and lacks targeted
therapies, resulting in decreased disease-free survival(2, 6, 7).
The standard line of care for TNBC patients includes a combination of paclitaxel, a mitotic
inhibitor, and anthracycline, a DNA intercalator, but many patients quickly develop resistance and

Figure 1- Reprinted with permission. © (2018) American Society of Clinical Oncology, From
Liedtke et al. 2008. Survival outcomes of TNBC patients. TNBC patients who achieve pCR (blue
line) have comparable outcomes to non-TNBC patients who also achieve pCR (yellow line).
However, TNBC patients who fail to achieve pCR (dotted red line) have significantly worse longterm outcomes than other breast cancer patients.
are left with no further treatment options. Although studies indicate that TNBC tumors are more
sensitive to high-dose chemotherapy than ER positive tumors(8, 9), chemoresistant TNBC patients
who fail to achieve a pathological complete response (pCR) have significantly worse prognoses than
non-TNBC breast cancer patients who also fail to achieve pCR(7, 9). In the neoadjuvant
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chemotherapy (NAC) setting, TNBC patients who achieve pCR have long-term survival rates
comparable to non-TNBC patients with pCR (Figure 1). However, the clinical trajectory diverges
with in the absence of pCR: TNBC patients who fail to achieve pCR have significantly worse survival
outcomes than non-pCR patients of other breast cancer subtypes (Figure 1).
Studies in pharmacogenomics have categorized gene clusters that may predict resistance to
paclitaxel or anthracycline(5, 10), but none have traced the genomic and phenotypic evolution of
tumor cells at the resolution required to identify rare, resistance-associated populations. Studies in
cancer genomics have characterized the clonal genotypes of TNBC tumors(11) as well as their
extensive intratumor heterogeneity(12) and high frequency of TP53 mutations(13), but none have
investigated longitudinal changes in genotypic and phenotypic subclones. Moreover, studies in
residual disease after NAC have identified resistance-associated transcripts and biomarkers(14, 15),
but none have analyzed the evolution of somatic mutations, copy number variations, and
transcriptomes at the resolution necessary to resolve rare genotypes and phenotypes.
Some of these gaps in knowledge exist because we have only recently come to understand the
heterogeneous nature of TNBC in terms of differences between tumor cells within the same tumor
(intratumor heterogeneity [ITH]). In 2011, Navin et al. published the first single cell sequencing
study, which identified diverse copy number aberrations (CNAs) between individual cells from one
TNBC tumor. Since then, an increasing number of single-cell studies have focused on CNAs with
expanded patients cohorts(16), somatic mutations(17, 18), and transcriptional profiles(19) and have
substantiated TNBC ITH on multiple levels.
The complex genotypic and phenotypic diversity of TNBC cells introduces the possibility
that single cell sequencing is necessary to identify resistance-associated subclonal populations,
because standard bulk sequencing will average the signals from copy number aberration (CNA)
subclones or transcriptional subclones. With exome sequencing, it is only possible to establish the
subclonal structure of tumors if they are sequenced at a sufficiently high depth. To account for
TNBC ITH in my investigation of chemoresistance evolution, I conducted deep-exome sequencing,
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single-cell copy number sequencing, and single-cell RNA sequencing on longitudinal treatment time
points attained from n=20 TNBC patients.
My thesis is based on the core principles that guide both species evolution and tumor
evolution. In the following chapters, I will explain the evolutionary rationale for my study, followed
by a description of the technical innovations and experimental approaches that have made it possible
to investigate the evolution of chemoresistance in triple-negative breast cancer.
1.2 Principles of [Tumor] Evolution
1.2.1 Darwinian Evolution
Darwinian evolution provides the intuitive foundations of bottlenecks and selection, which are
essential in studying both single tumor cells and tumor populations.
In 1859, Charles Darwin proposed
“Let it be borne in mind how infinitely complex and close-fitting are the
mutual relations of all organic beings to each other and to their physical conditions
of life. Can it, then, be thought improbable, seeing that variations useful to man
have undoubtedly occurred, that other variations useful in some way to each being in
the great and complex battle of life, should sometimes occur in the course of
thousands of generations?”
–

Charles Darwin, “On the Origin of the Species by Means of Natural Selection,
1859”

An avid naturalist, Darwin was acutely aware of the variations that occurred in species by means of
both conscious and unconscious selection. He noted the random variation in breeds of domestic
pigeon – from the “wide gape of mouth” on the English carrier to the “beak in outline almost like
that of a finch” on the short-faced tumbler – as well as the variation in a myriad of other plant and
animal species he encountered during his voyages. Darwin extrapolated from these observations that
certain variations allowed individuals to be better suited for specific conditions, thereby imparting
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“some advantage over a different set of competitors or enemies” in the “struggle for life”. Without
any knowledge of genes and genetic heredity, he postulated that a favorable variation, governed by
random mutation, would “maintain itself in a body and afterward spread, so that the individuals of a
new variety would chiefly cross together” to create offspring who also carried those traits.
Environmental factors, including availability of resources, would exert the non-random pressures that
select for the persistence and propagation of variations that are conducive to survival.
Although cancer cells do not reproduce sexually, they have genomic and phenotypic
variations that confer fitness advantages and undergo natural selection. In the context of drug
resistance, therapies produce an exogenous selective pressure that eliminates susceptible cells but
leaves behind resistant cells to repopulate the tumor after treatment(20). In an alternative
evolutionary route, therapies, via genotoxic damage or other mechanisms, can also elicit the
variations that enable drug resistance(20). Regardless of the mode by which variations arise,
Darwinian dynamics govern the selection of variations that confer a fitness advantage to individuals
and to cancer cells. We do not consider a tumor cell to be a physiological tabula rasa but rather a
genetically unique entity with various predispositions that guide survival, drug resistance, metastasis,
etc.

1.2.2 Modern Applications to Cancer Evolution
Peter Nowell’s seminal paper published in 1976 posited that cancer progresses in a sequential
fashion, propagated by the stepwise Darwinian selection of subclones(21). This process involves
potential trajectories that become more or less plausible depending on the data set, the context of
tumor sequencing, and the types of genomic analyses conducted(22). Place Darwin’s tree of life next
to any contemporary tumor phylogenetic tree, and you will notice the similarities in the selection of
subclones that have favorable genomic characteristics. For instance, the linear evolution model
suggests that new clones with driver mutations outcompete previous clonal populations,
overpowering the tumor mass, as evidenced by colorectal cancer progression, where an ordered
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accumulation of genetic alterations depicts the transition from normal epithelium to adenoma to
carcinoma(23). Deep whole genome sequencing (WGS) also indicates linear evolution in acute
myeloid leukemia (AML) patients who relapse after chemotherapy(24), and loss of heterozygosity
analyses reveal linear evolution in high-grade serous epithelial ovarian cancer patients with
metastases(25), indicating that linear evolution can emerge in different clinical settings. Although
linear evolution largely decreases ITH, the amount of heterogeneity detected depends on the time

a

b

c

d

Figure 2 - From Davis et al. 2017. Modes of tumor evolution. Representations of linear and
branching evolution (a), where linear evolution displays stepwise replacement of preceding clones
and branched evolution displays co-existence of diverging subclones (b). Shown also: neutral
evolution (c) and punctuated evolution (d) : Davis A., Gao R., Navin N (2017). Tumor evolution:
Linear, branching, neutral or punctuated? Biochimica et Biophysica Acta (BBA) – Reviews on
Cancer. License number: 4316580586200.
point of investigation, because a tumor may be sampled at a stage where the dominant clone has not
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yet outcompeted its predecessors(26). However, many studies in linear evolution have used single
genes as opposed to genome-wide markers, limiting the accuracy of the model in solid tumors(22).
Conversely, the branching evolution model provides a scenario where clones evolve in
parallel, resulting in a multiclonal tumor and giving rise to ITH via mutations, copy number
aberrations, and epigenetic changes. Numerous examples of branching evolution exist in the
literature, including metastatic renal cell carcinoma(27), primary breast cancer(28), multifocal prostate
cancer(29), brain metastases(30), hepatocellular carcinoma(31), among others. Notably, even tumor
types that display linear evolution in some scenarios can display branching evolution in others (e.g.
investigating treatment-naïve progression versus pre- and post-treatment samples), alluding to the
context-specificity of tumor evolution.
In neutral evolution, there are no shifts in clonal fitness over time, and subclones effectively
grow at similar rates(32), while punctuated evolution is demarcated by early bursts of genomic
instability followed by periods of relatively stable clonal expansion (Figure 2) (33). We see some
aspects of these models in colorectal cancers that expand as multiple intermixed subclones after a
“big bang” of genomic instability(34). Neutral evolution, however, contrasts with Darwinian
principles because it excludes clonal selection as a driver of tumor evolution – but studies on neutral
evolution are hampered by low-depth data that cannot accurately resolve subclones(32). In addition,
there is a possibility that not all identified clones will neutrally progress; clones can compete across
longitudinal time points, decreasing in number according to relative fitness as time passes.
What then is the “most accurate” model of evolution? Does one even exist? To date, the
vast quantity of literature that has been accumulated on tumor evolution strongly supports linear or
branching trajectories, although there is no way to predict a priori the model that a patient will follow.
This is further complicated by the fact that there are different genomic evolutionary clocks operating
within a tumor: for example, copy number evolution has been shown to be punctuated, while
mutations accumulate throughout tumor evolution(22). We can presume that certain tumors display
certain evolutionary trajectories due to variations in the tissues of origin, the selective pressures
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incurred by the microenvironment, or the clinical treatment regimen, but all these are suppositions
that must be rigorously tested. Nonetheless, it is important to note that both linear evolution and
branching evolution are adaptations of Darwinian theories that signify the wider applicability of
Darwinian evolution to cancer.
1.2.3 Intratumor Heterogeneity
We are now aware that tumors are dynamic ecosystems, reflecting an evolutionary course of
polyclonal expansions, whereby resilient clonal populations are positively selected to expand in
response to selective pressures(27, 35, 36). Cancer progression, metastasis, and drug resistance are
not uniform processes but are characterized by the complex biology of intratumor clonal
competition. These considerations are further complicated by the genotypic, phenotypic, and
epigenetic heterogeneity across different geographical regions and even across single cells within
individual tumors. Despite their respective drawbacks, whole-exome sequencing (WES), WGS,
multi-region sequencing, and single cell sequencing provide snapshots of ITH and show which
genotypic or phenotypic aberrations are conserved across the majority of spatial regions and single
cells as early events. For example, one area of a tumor may have unique subclonal mutations or
CNAs that are absent in other regions. Intratumor variations are clinically important, because
therapies may target subclonal aberrations that exist in only a fraction of the tumor. Those cells that
are susceptible to the therapy will be eliminated, while non-susceptible resistant cells will remain
unaffected and persist as resistant disease.
With ITH, different subclones within a tumor display clonal competition for resources(37),
but clones can coexist in many circumstances. Merlo and colleagues list the ecological reasons for
clonal coexistence in their 2006 review paper(37) and emphasize that fitness can decrease due to
immune predation or clonal parasitism as clones increase in size, allowing competing clones to
maintain their populations. Furthermore, clones may experience physical barriers that separate them
from other clones(38) or adapt to particular niches(39) so that they occupy non-overlapping
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resources. Clonal cooperation is also possible, wherein two or more clones are together necessary
for tumor propagation(40), and a single clone is insufficient to drive tumor growth.
Regardless of whether ITH emerges as a stable state (neutral evolution) or as a transient state
(linear and branched evolution), it encompasses many genomic and phenotypic layers. The models
discussed in the previous section focus mainly on data from somatic mutations or CNAs, but ITH in
cancer is also prevalent at the transcriptomic and epigenetic levels. Tri-omic sequencing methods
(scTrio-seq(41)) resolve intratumor subclonal populations based on CNAs, DNA methylation, and
transcriptomes in hepatocellular carcinoma, and there is a large body of literature that documents the
roles of single-cell RNA sequencing(19, 42-48) and various modes of epigenetic analyses(49-51) in
resolving the phenotypic heterogeneity of tumors. The amount of ITH detected in the genome
versus the transcriptome or epigenome has not yet been studied in-depth, but the phenotypic
evolution of transcription and epigenetics can perhaps explain why genomic mutations or CNAs are
not the only important aspects of tumor growth. Controversially, a study published in 2015(52)
posited that tumor initiation could be attributed to “bad luck”, or the accumulation of carcinogenic
mutations arising randomly during DNA replication(52). However, this study did not evaluate the
contributions of transcriptomic and epigenetic clonality in cancer.

1.2.4 Evolutionary Patterns of Resistance
The identity of resistant subclones is largely dependent on the evolutionary trajectory of the
tumor, as discussed in detail in Section 1.2.2 and 1.2.3. However, ITH in itself can provide insight
on the probability of resistance. Analyses of chronic lymphocytic leukemia patients show that the
mere presence of a subclonal driver mutation is an independent risk factor for disease progression
after treatment(53), suggesting that subclones have the ability to impart fitness advantages.
Therapeutic agents can be regarded as inducing evolutionary bottlenecks that eliminate susceptible
tumor cells and select for resistant populations. It is unclear whether drug resistance arises due to the
selection and expansion of rare pre-existing subclones (adaptive resistance), or, alternatively, through
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the induction of new mutations that confer a chemoresistant phenotype (acquired resistance)(54).
This question has been studied extensively in bacterial systems since the seminal fluctuation
experiments by Luria & Delbruck(55) in 1952 but remains poorly understood in most human
cancers.
There are many limitations to investigating response to therapy in cancer patients: specimen
availability, specimen quality, and sequencing techniques all restrict the type of studies that can be
conducted. Genotypic evolution, via WGS and WES, has been more frequently studied in the
context of cancer therapy than phenotypic evolution, largely because WGS and WES are wellcharacterized, common next-generation sequencing methods in clinical and translational cancer
research. Furthermore, WGS and WES are also more widely applicable to clinical samples than bulk
or single-cell RNAseq, because DNA is not as susceptible to degradation as RNA. Although existing
examples of genomic bottlenecks are largely derived from WGS and WES, we can predict that with
recent advances and modifications in nucleus-based RNAseq, the mechanisms of phenotypic
evolution will be elucidated for multiple cancer types in the near future.
Genomic investigations of resistance to targeted therapies often involve compensatory
activities and alterations in related pathways. For instance, studies indicate that ER-positive
metastatic breast cancer patients acquire resistance to endocrine therapy via activating ESR1
mutations(56), castration-resistant prostate cancer patients acquire resistance to androgen receptor
antagonists via a F876L mutation in the androgen receptor(57), and colorectal cancer patients acquire
resistance to EGFR blockade via different KRAS mutations(58). Alternatively, there are numerous
examples of adaptive resistance at the genomic level: pre-existing MEK1 mutations confer resistance
to BRAF inhibitors in metastatic melanoma(59) and pre-existing BRC-ABL kinase domain mutations
confer resistance to a tyrosine kinase inhibitor in chronic myeloid leukemia(60). Resistance to
targeted therapy can also occur at the phenotypic level, involving RNA expression changes in the
absence of explicit somatic mutations. BRAF(V600E) mutant melanomas acquire increased EGFR
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expression(61) and decreased miR-579-3p expression after developing resistance to BRAF
inhibitors(62).
Mechanisms of resistance in non-targeted agents like chemotherapies have been more
difficult to understand, because these drugs can have widespread genotypic and phenotypic effects.
Even within the sample tumor types, the evolutionary patterns detected by WGS and WES can vary
from patient to patient. In AML, WGS before and after chemotherapy (and subsequent relapse)
reveals different modes of clonal evolution, with some patients gaining relapse-specific mutations
and others demonstrating a post-treatment expansion of minor clones that existed before
treatment(24). In high-grade serous ovarian cancer, platinum-based chemotherapy seems to induce
somatic mutations in acquired resistance(63), while resistance to cytotoxic chemotherapy in bladder
urothelial carcinomas is determined by the persistence of pre-existing cell populations(64).
Previous work on chemoresistance in TNBC patients has focused mainly on in situ
hybridization methods(65) and bulk genomic profiling methods(14, 15). Using DNA-FISH and IHC
for a limited set of markers, the authors of one study showed that genetic diversity did not change in
response to NAC but mesenchymal phenotypes were selected(65). Another study used nextgeneration sequencing to profile residual disease in post-treatment TNBC chemotherapy samples and
identified a number of clinically-actionable mutations(15) including TP53, MCL1 and MYC, that
could be targeted after patients become resistant to chemotherapy. A third study identified 9p24
amplifications of JAK2 associated with resistance to chemotherapy in TNBC patients, also providing
an addition therapeutic target(66). However these investigations have neither addressed the
evolutionary question of adaptive versus acquired resistance in TNBC nor have they accounted for
the considerable genotypic and phenotypic ITH of TNBC tumors.

1.3 Cancer Genotype and Cancer Phenotype
1.3.1 Beyond DNA
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The changes that occur in tumors during cancer therapy are multifaceted, involving multiple
alterations in the genome, transcriptome, epigenome, and proteome(54, 67, 68). Although studies
have largely focused on DNA alterations, it is critical not to overlook the various factors that
contribute to a phenotypic effect. The distinction between a driver mutation and a passenger
mutation becomes particularly significant, because not every genotypic aberration influences the
fitness of a tumor cell. Likewise, an mRNA transcript may not exert downstream signaling effects,
because post-transcriptional modifications can prevent its translation.
There are algorithmic tools that predict and annotate the functional significance of somatic
mutations from WES or WGS data (e.g. Polyphen(69), SIFT(70, 71)) by using nonsynonymous
mutations to evaluate the impact of variants on protein structure and function. Network analyses
can piece together protein-protein interactions, genetic interactions, and drug-gene interactions to
understand the functional interactions of genes and proteins(68). However, these tools are
probabilistic through computational methods or low-throughput through experimental methods.
Moreover, predicted amino acid changes do not always indicate proteomic consequences, and we
have not yet optimized an experimental way to connect the various aspects of genotypic and
phenotypic evolution in a clinically relevant cancer context.
The interplay between cancer genotype and phenotype is important to understand, because
there can be a discordance between the genotypic evolutionary trajectory and the phenotypic
evolutionary trajectory. The classification system for breast cancer in itself is an example of such
dissonance: breast tumors are canonically categorized into subtypes (basal-like, HER2+, normalbreast-like, luminal epithelial/ER+) according to gene expression(72), but TNBC tumors, which
largely comprise the basal-like group, share very few common somatic mutations across patients(13).
In a study conducted in 2014, Almendro and colleagues used ImmunoFISH and found that breast
cancer patients who achieved a partial response or no response to NAC did not display changes in
intratumor genotypic diversity but did display observable alterations in phenotypic diversity(65). This
integrated analysis of cancer genotype, phenotype, and spatial organization shed light on therapy-
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related tumor evolution in multiple capacities(65). Nonetheless, the use of ImmunoFISH precluded
an unbiased analysis of genome-wide changes, and there is still a gap in knowledge regarding the full
extent of genomic and phenotypic evolution in breast cancer.
In ideal circumstances, it would be possible to easily assess multiple aspects of tumor
evolution from the same cell. As it stands, most genotype-phenotype association experiments either
use a limited number of biomarkers or conduct sequencing on different sets of cells. Two methods
published in 2015, G&T-seq(73) and DR-seq(74), allowed simultaneous genome and transcriptome
sequencing from a single cell, but these methods remain very low-throughput and expensive, and the
resulting data have many technical errors due to the physical separation of DNA and RNA prior to
amplification in each cell.

1.3.2 Gene Dosage Effects
Similar to somatic mutations, somatic CNAs often exert unclear effects on gene expression.
Although copy number amplification is broadly correlated with increased gene expression and copy
number deletion is broadly correlated with decreased gene expression, the associations are not quite
as straightforward, because there are numerous components that regulate gene expression, such as
chromosomal hypermethylation. A study of 77,840 tumor expression profiles observed that 98.9%
of expressed genes were positively correlated with copy number after accounting for non-genetic
transcriptional components(75). In contrast, an investigation of the copy number-altered genome in
cervical cancer patients showed that only 22.9% of dysregulated genes were copy number-altered(76).
In breast carcinomas, a subset of genes had a significant correlation between mRNA levels and
CNAs, but some genes with normal copy number profiles also displayed clinically significant
expression changes(77). Perhaps these non-linear relationships can be explained quantitatively: in a
CNA analysis across 6,691 human genes, a 2-fold change in DNA copy number resulted in a 1.5-fold
change in mRNA levels(78). The comparatively smaller change in mRNA may be normalized and
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thus overlooked depending on the methods of data analysis and the expression of other detected
genes.
On a more global level, aneuploidy of transcriptional regulators in certain regions of the
genome can influence transcription in genes that reside on other chromosomes(79). Furthermore,
aneuploidy can elicit alterations in cell-cycling and create transcriptional changes in pathways related
to metabolism, inflammation, and cell stress responses(79). Heterozygotes with null alleles of tumor
suppressor genes can be haploinsufficient and promote tumorigenesis in particular genetic
backgrounds(80), revealing the importance of context in gene dosage.

1.3.3 Phenotypic Plasticity and Transcriptional Reprogramming
Phenotypic plasticity is generally defined as the capacity of a genotype to produce different
phenotypes(81) and to consequently enable rapid adaptation in a variety of contexts. In healthy cells,
plasticity permits beneficial flexibility: plasticity in vascular smooth muscle cells allows repair in
response to injury(82), plasticity in nephron development converts the metanephric mesenchyme to
an epithelial phenotype(83), etc. In cancer cells, phenotypic plasticity yields congruous effects on
tumor fate, promoting cellular processes that are conducive to progression, metastasis and survival.
A prime example of this is the phenomenon of epithelial-to-mesenchymal transition (EMT), where
an epithelial cell acquires changes that portend a mesenchymal cell phenotype(84, 85). Pleiotropic
transcriptional repressors such as Snail, Slug, Zeb1, and Twist suppress markers of epithelial
adhesion(86), propagating cancer metastasis. This transformation, while standard in normal
developmental processes, lets carcinoma cells separate from adjacent cells and disseminate to both
local and distant tissue regions. Mesenchymal features can also desensitize tumors to cytotoxic
agents and render them chemoresistant(87, 88).
Interactions between tumor cells and the tumor microenvironment contribute to the
dynamics of phenotypic plasticity, and tumor cells can be reprogrammed in conjunction with changes
in their neighboring cells, signaling agents, and resources. For example, M2 macrophages induce
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EMT when co-cultured with epithelial breast cancer cells(89), and microenvironmental factors like
glutamine deprivation and TNFα cause melanoma cell de-differentiation(90). Hypoxia can elicit
phenotype switching of ROR1-positive melanomas to the ROR2-positive phenotype that is more
invasive(91). In hepatocellular carcinomas (HCCs) with constitutive AKT-1 activation, chronic liver
inflammation caused by 3,5-diethoxycarbonyl-1,4-dihydrocollidine can increase cellular growth and
proliferation while up-regulating critical genes that contribute to HCC progression(92). Even
physical considerations like fluid shear stress versus static culture can elicit EMT in esophageal cancer
cells(92).
Indeed, the concept of phenotype plasticity is important in cancer therapy, because it posits
that cells can reprogram from a less invasive state to a more invasive state and vice versa under cellintrinsic or cell-extrinsic conditions. Phenotypes are more amenable to adaptive modifications than
genotypes, because they can change accordingly under the cellular or microenvironmental pressures
of therapy. While there is much that remains unknown about the precise mechanisms of phenotypic
plasticity, a growing number of studies are investigating the role of epigenetics in tumor therapy
resistance, because epigenetic adaptations like DNA hypermethylation of gene promoters are known
to drive chemoresistance across many cancer types(93). Case in point, methylation leads to
transcriptional downregulation of key genes in non-small cell lung cancer, resulting in resistance to
cisplatin(94). Likewise, methylation of the hMLH1 promoter in ovarian cancer is associated with
cisplatin resistance, and exogenous inhibition of methylation re-instates hMLH1 expression and drug
sensitivity(95). In alternate scenarios, methylation can be a positive marker for drug sensitivity, as in
the case of O6-methylguanine-DNA methyltransferase (MGMT) and temozolomide in glioma:
epigenetic silencing of MGMT is correlated with glioblastoma sensitivity to alkylating agents, leading
to longer overall survival(96).

1.4 Relevant Methodology in Evaluating Tumor Evolution via Single Cell Sequencing
1.4.1 DNA Mutation Profiling Methods
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Although whole-exome sequencing panels overlook noncoding mutations that may have regulatory
functions(97, 98), bulk WES is a more affordable means of elucidating ITH, because the exome is
only ~2% of the genome, and subclonal and clonal mutations can be detected in WES data for clonal
analyses(99-101). However, in order to measure clonal substructures, bulk WES data require
estimations of tumor copy number and tumor purity and do not represent the spatial diversity of
solid tumors. One method of accounting for spatial ITH is multi-region sequencing, where different
sections of a tumor are sampled and sequenced in order to measure genomic diversity. In ovarian
cancer, multi-region sequencing demonstrates spatial variation in terms of somatic mutations, copy
number aberrations, and gene expression, with canonical ovarian cancer drivers altered in only a
subset of regions(102). The same is true for other cancer types, including breast cancer(28), renal cell
cancer(27, 36), lung cancer(103, 104), colorectal cancer(105), and prostate cancer(29). The limitations
of multi-region sequencing, however, are related to clinical feasibility, because it is simply impossible
to acquire multiple biopsies in most clinical scenarios. While the approach has been enlightening
from a genomic perspective, it is not practical enough to be broadly applied to a large number of
patient cases. Furthermore, multi-region sequencing is even less realistic in studies of therapy
resistance that require longitudinal samples from ≥2 treatment time points.
An alternative way to gauge ITH is single cell sequencing, where single cells from a tumor
are isolated and profiled for copy number aberrations(12, 16, 106), somatic mutations(17, 18, 107),
gene expression(42, 108-112), or epigenetic modifications(49, 113-115). In contrast to multi-region
sequencing, single cell sequencing can be conducted on individual biopsies, resolving genotypic and
phenotypic differences across single cells from relatively small tissue samples. Nevertheless, single
cell sequencing has its own unique restrictions. Though the cost-related limitations of single cell
sequencing have been mitigated to some degree by high-throughput multiplexing techniques, single
nucleotide variant (SNV) detection in single cells is hampered by the amplification biases of WGA,
and gene expression analyses in single cells are hindered by sparse gene detection. There are
different methods of WGA, including multiple annealing and loop-based amplification
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(MALBAC)(116), which uses the Bst polymerase, and Phi29-based multiple-displacementamplification (MDA)(17), which has fewer false positives than Bst-based MDA. Regardless, further
technical improvements are needed to enhance the sensitivity and specificity of single cell sequencing
for SNVs.
Validated panels can be particularly useful in single cell sequencing because they encompass
a smaller region of the exome and therefore yield a higher coverage depth than WES panels at the
same number of lanes sequenced. These panels can be customized to include genes that inform
clinical decisions, as in The University of Texas MD Anderson Cancer Center’s “T200” panel(117),
which incorporates 201 genes relevant to cancer from the Catalogue of Somatic Mutations in Cancer
(COSMIC)(118) and The Cancer Genome Atlas (TCGA). Targeted multigene panels are currently
being tested on bulk tissue from numerous clinical settings, such as hereditary cancer risk
assessment(119), and can feasibly inform ITH when applied to single cells.

1.4.2 DNA Copy Number Profiling Methods
Many clinical genetics laboratories now evaluate CNAs, copy number variants (CNVs), and copy
number polymorphisms (CNPs) with single nucleotide polymorphism (SNP) arrays or comparative
genomic hybridization (CGH) methods(120-122). Nonetheless, SNP arrays are limited by probe
distribution and availability, and CGH methods are limited by their inability to accurately determine
genome-wide loss of heterozygosity (LOH)(123). As an alternative, low-coverage WGS is an
unbiased way to sample copy number, delivering high-breadth coverage of the genome and the
opportunity to discover new breakpoints in samples. The first single-cell CNA sequencing method
was developed in 2011 and used WGA on flow-sorted frozen single cells to create next-generation
sequencing libraries. Since then, single-cell copy number sequencing has been applied to a variety of
tumor types and sample types, including formalin-fixed paraffin-embedded samples(106).
Multiplex sequencing allows many individually amplified and barcoded sample libraries to be
sequenced on a single lane and then be sorted during the data analysis process to increase cost-
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efficiency. For example, SCI-seq uses nucleosome depletion followed by combinatorial indexing to
sequence thousands of single cells(124), which are demultiplexed during data analysis. Degenerativeoligonucleotide-PCR (DOP-PCR)(12, 125) is often used in the WGA step prior to sequencing library
construction, but recent developments allow direct tagmentation of single-cell DNA without
preamplification(126).

1.4.3 RNA Sequencing Methods
New single-cell RNA sequencing methods have distinguished tumor and stromal cell types and have
led to an improved understanding of cell plasticity and transcription in solid tumors(42, 47, 127).
Very generally, single-cell RNAseq involves single-cell isolation and mRNA capture followed by
reverse-transcription and amplification of cDNA(128). Early iterations of the method include cell
isolation by micropipeting, laser capture microdissection, or fluorescence-activated cell sorting
(FACS), although recent advances permit more high-throughput techniques, such as microfluidic and
microdroplet cell capture(128).
There are also differences in the RNAseq chemistry across the methods(129): some systems
like Smart-seq/C1(130) and Smart-seq2(131) sequence the full-length transcript at the exclusion of
unique molecular identifiers (UMIs). In contrast, systems like Drop-seq(112) and MARS-seq(132)
use UMIs in the absence of full-length sequencing. Newly released manuscripts(133) (including the
one featured in Section 3.1) have evaluated the potential of single-nucleus RNAseq as a surrogate for
single whole-cell RNAseq - the relative advantages of which will be described in Section 3.1.
Overall, flexible phenotypes influence clinical trajectories in patients, and (as conducted in
my thesis) it is therefore meaningful to study genotypes in conjunction with phenotypes when
tracking tumor evolution during therapy. Genotypes inform of us of mutational processes and copy
number aberrations in DNA, while phenotypes inform us of flexible transcriptional alterations that
dictate cell behavior. My thesis assesses somatic mutations from bulk tumor populations, single-cell
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CNAs, and single-cell transcriptomes (albeit all from different cells) to study tumor evolution beyond
mere DNA alterations.

1.5 Dissertation Summary
Triple-negative breast cancer (TNBC) is an aggressive subtype that often develops resistance to
chemotherapy. An unresolved question is whether resistance is caused by selection of rare preexisting clones, or alternatively through new mutations that are induced by the therapy. To
investigate this question, we applied single cell DNA and RNA sequencing, and bulk deep-exome
sequencing to longitudinal samples from 20 TNBC patients during NAC. Deep-exome sequencing
identified 9 patients where NAC led to clonal extinction and 11 patients where clones persisted after
NAC. Single-cell DNA sequencing of 900 cells from 8 patients showed that pre-existing copy
number profiles were adaptively selected by NAC. In contrast, single-cell RNA sequencing of 6,862
cells in 8 patients showed that NAC induced new transcriptional programs that conferred a
chemoresistant phenotype. Our data suggest a model for chemoresistance in which adaptive
selection of genotypes is followed by the transcriptional reprograming of chemoresistant phenotypes.
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CHAPTER 2: MATERIALS AND METHODS
[Note: This chapter is based on published material from Gao and Kim et al. 2017 (Gao, R and Kim,
C. et al. Nanogrid Single-Nucleus RNA Sequencing Reveals Phenotypic Diversity in Breast Cancer
Nat Commun 8, doi:doi:10.1038/s41467-017-00244-w, 2017) as well as a manuscript that has been
accepted by Cell (Kim and Gao et al. 2018). Nat Commun articles are published under a CC BY
license (Creative Commons Attribution 4.0 International License), which establishes that authors
retain copyright in their articles.]

2.1 Materials
2.1.1 Human Patient Cohort
Fresh triple-negative breast cancer (TNBC) tissue samples were obtained from the Predict Response
of Preoperative Treatment of Breast Cancer Early (PROMIX: NCT00957125) trial in collaboration
with Dr. Theodoros Foukakis at the Karolinska University Hospital and with material transfer
agreement (MTA) approval by the Internal Review Board (IRB) at the University of Texas MD
Anderson Cancer Center and Karolinska University Hospital. The triple-negative status of all tumor
samples was determined by standard immunohistochemistry.
The PROMIX trial recruited patients with localized, primary breast cancer, including
inflammatory breast cancer, suitable for primary medical treatment and/or patients with regional
lymph node metastases, including ipsilateral supraclavicular nodes, with breast cancer diagnoses
confirmed by histological examination with or without tumor lesions in the breast (Figure 3).
PROMIX’s purpose was to evaluate patient response to six cycles of chemotherapy with epirubicin
and docetaxel +/- bevacizumab by mammography, ultrasound, several functional imaging techniques
(MR, CT-PET, contrast-enhanced ultrasound), and biological markers detected from fresh tumor
samples. The trial adhered to the ethical principles recommended by the Declaration of Helsinki,
was approved by institutional review, and followed the quality standards of Good Clinical Practice
(GCP).
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Tumor tissue samples were collected <2 weeks prior to treatment initiation (14G core
biopsy), after 2 cycles of 75 mg/m2 epirubicin and 75 mg/m2 docetaxel (14G core biopsy), and after
4 additional cycles of 75 mg/m2 epirubicin and 75 mg/m2 docetaxel in combination with 15 mg/kg
SD/PR

pre-treatment
core biopsy

mid-treatment
core biopsy

post-treatment
operative excision

2 cycles
Epirubicin +
Docetaxel

6 cycles
Epirubicin +
Docetaxel +
Bevacizumab

Figure 3 - Timeline of chemotherapy treatment schedule and sample acquisition. A pre-treatment
core biopsy was obtained prior to NAC, a mid-treatment core biopsy was attained after two cycles of
NAC (docetaxel and epirubicin), and the surgical sample was obtained after four additional cycles of
NAC in combination with bevacizumab.
bevacizumab (surgical excision). Tumor tissue from the 14G biopsies were placed on microscope
slides for imprinting and then dry-compressed without addition of fluids. Afterwards, samples were
placed in tubes and snap-frozen immediately or after a maximum delay of 10 minutes. We
retrospectively received the de-identified frozen samples for genomic analyses.

2.1.2 Breast Cancer Tissue Samples and Cell Lines for Nanogrid Single-Nucleus RNA Sequencing Validation
Breast cancer cell lines were obtained from Characterized Cell Line Core (CCLC) Facility at the
University of Texas M.D. Anderson Cancer Center, Houston, TX to validate our nanogrid-based
single-nucleus RNA sequencing technology. All cell lines were mycoplasma-negative and
authenticated with the Short Tandem Repeat (STR) method by the CCLC facility. Fresh tumor
tissue from an invasive ductal carcinoma patient was obtained in collaboration with Dr. Hong Zhang
at MD Anderson Cancer Center, under approval by the Internal Review Board (IRB) at the
University of Texas MD Anderson Cancer Center. The triple-negative status of this tumor sample
was determined by IHC for estrogen receptor (<1%) and progesterone receptor (<1%), and FISH
analysis of HER2 amplification using the CEP-17 centromere control probe (ratio of HER2/CEP-17
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< 2.2). This tumor sample was also used in the technology development and validation steps for our
single-nucleus RNA sequencing system.

2.2 Application of Existing Bulk Next-Generation Sequencing Methods
2.2.1 Whole-Exome Sequencing
Bulk genomic DNA was extracted from frozen tumor samples following the manufacturer’s
instructions outlined in the DNA Mini Kit (Qiagen, #51306). Germline genomic DNA was
extracted from matched patient blood samples with the DNA Blood Mini Kit (Qiagen, #51106).
Extracted DNA was sonicated to 250 bp using the S220 Sonicater (Covaris). KAPA Hyper libraries
(KAPA Biosystems, #8502) were constructed from the sonicated DNA according to manufacturer’s
instructions using 10-250 ng of input DNA and unique NEXTflex-96 barcodes (Bio Scientific) for
each individual sample. Libraries (8-12) were pooled together and underwent exome captures using
the SeqCap EZ v2 (Roche, #06953212001), which constituted 44 Mb of the genome. Final v2
exome capture products were quantified with Qubit dsDNA HS Fluorometric Assay, Agilent’s High
Sensitivity DNA Chip, and KAPA HIFI and sequenced at 100 paired-end cycles on the HiSeq2000
or HiSeq4000 system (Illumina) in the Sequencing Core Facility of the Genetics Department at MD
Anderson Cancer Center.

2.2.2 Targeted Amplicon Sequencing
Forward and reverse primers were designed to incorporate ~150 bp regions containing the variant
sites of interest identified by bulk exome sequencing for the tumor sample and its matched blood
sample. Amplicons were PCR-amplified, purified, eluted in ~20µL H2O, and run on an agarose gel
to confirm fragment sizes. They were then pooled together in equimolar concentrations and
sonicated to 250 bp. A New England BioLabs kit was used for end repair of amplification products
(NEB, E6050L), and amplicon products were subsequently purified with the DNA Clean and
Concentrator-5 Kit (Zymo Research, #2404). The NEBNext DNA Library Prep enzymes were used
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for 3’ adenylation, adapter ligation, and PCR amplification to barcode the library with a P7 unique 8bp identifier. The final barcoded library was quantified by quantitative PCR using the KAPA Library
Quantification kit (KAPA Biosystems, KK4835) and the QuantStudio 6 Flex Real-Time PCR System
(Thermo Fisher Scientific). The sample was placed on the MiSeq system (Illumina) for sequencing.

2.3 W hole-Exome Sequencing Data Analysis
2.3.1 Variant Calling
FASTQ files were mapped to the human assembly US National Center for Biotechnology
Information build 37 (hg19) using the Bowtie2(134) alignment software. Samtools (0.1.19)(135) was
used to convert SAM files to compressed BAM files and to sort the BAM files by chromosomal
coordinates(135). PCR duplicates were marked with Picard (1.56), and the sorted, marked BAM files
were realigned with the Genome Analysis Toolkit (GATK 1.4-37)(136) at intervals with indel
mismatches. GATK was also used to detect single nucleotide variants (SNVs), and all samples within
an experiment were processed into one VCF4 file. Variants that had at least 30x coverage across all
corresponding longitudinal and matched blood samples were selected and further filtered so that a
mutation was only considered a true mutation if it met the aforementioned criterion and had at least
5 variant reads. Germline variants were removed by filtering out variants in the normal samples, and
SNVs and indels were annotated downstream with Annovar(137), dbSNP build135(138),
1000Genomes(139), Polyphen(69), SIFT(70, 71), MutationTaster(140), and COSMIC(118).

2.3.2 Mutation Clustering
Non-synonymous somatic mutations were identified in the bulk exome sequencing data for 20
TNBC patients with 2 or 3 longitudinal samples. Bulk tumor genomic copy number profiles were
estimated from the pair-end exome sequencing depth using the R package ‘exomeCNV’(141). Tumor
purity was estimated as the maximum variant allele frequency in each tumor. The variant allele
frequencies from each point mutation were normalized with both exome-derived copy number
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profiles and estimated tumor purities, and initial clusters were identified using PyClone2
(v0.12.9)(142). Mutation clusters with only one mutation were excluded from further analysis. The
PyClone cluster frequencies were calculated as the mean variant allele frequencies of mutations
within each cluster. The final clonal inferences of somatic mutation were performed using
CITUP(143) by evaluating the optimal tree and the clustering adjustment across all the tumor time
points from same patient.

2.3.3 Targeted Amplicon Sequencing Data Analysis
Forward and reverse primers were designed to amplify ~150 bp regions containing the targeted
mutation site identified by bulk exome sequencing for the tumor sample and its matched blood
sample. Amplicons were PCR-amplified, purified, eluted in ~20µL H2O, and run on an agarose gel
to confirm fragment sizes. Fragments were pooled together in equimolar concentrations, and the
larger amplicons were sonicated. A New England BioLabs kit was used for end repair of
amplification products (NEB, E6050L), and amplicon products were subsequently purified with the
DNA Clean and Concentrator-5 Kit (Zymo Research, #11-303). NEBNext DNA Library Prep
enzymes were used for 3’ adenylation (#E6053L), adapter ligation (#M0202L), and PCR
amplification (#M0541L) to barcode the library with a P7 unique NEXTflex-96 barcode. The final
barcoded library was quantified by quantitative PCR using the KAPA Library Quantification kit. The
sample was sequenced on the MiSeq system (Illumina #MS-102-3001, 150 single-read).
DeepSNV(144) was applied to determine whether mutations were statistically significant and present
at higher levels in the tumor samples compared to the matched normal blood samples at a p-value <
0.05, with 5 bp flanking regions around the mutation site of interest to establish error rates.

2.4 Application of Existing Single-Cell Next-Generation Sequencing Methods
The protocol published by Gao et al. 2016 was used to multiplex single nuclei for copy number
sequencing. Briefly, nuclei from frozen tumors were isolated by mincing the tumor in DAPI-NST
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buffer (800 mL of NST [146 mM NaCl, 10 mM Tris base at pH 7.8, 1 mM CaCl2, 21 mM MgCl2,
0.05% BSA, 0.2% Nonidet P-40]), 200 mL of 106 mM MgCl2, 10 mg of DAPI, and 5mM EDTA)
and filtering through a 37-µM nylon-mesh filter(16). Single nuclei from the aneuploid distribution
were flow-sorted into 96-well plates through the FACSAria II flow cytometer. Each individual well
contained 10 µL of lysis solution from the Sigma-Aldrich GenomePlex WGA4 kit. The diploid
population DAPI fluorescence intensity was initially established with a lymphoblast diploid cell line
(REFM)(42).
Whole-genome amplification (WGA) was performed as described in the Sigma-Aldrich
GenomePlex WGA4 kit (WGA4-50RXN). The DNA concentration was measured (Thermo Fisher
Scientific, Qubit 2.0 fluorometer), run on gel electrophoresis for size distributions, and sonicated to
250 bp using the S220 Sonicater. The products underwent NEB end repair and were subsequently
purified with the DNA Clean and Concentrator-5 Kit. The NEBNext DNA Library Prep enzymes
were used for 3’ adenylation, adapter ligation, and PCR amplification to barcode each single-cell
library with a P7 unique 8-bp identifier (NEXTflex-96 barcodes, Bio Scientific) and common P5
adapter for sample multiplexing. After adapter ligation, libraries were purified with AMPure XP
beads 0.5x, and PCR-amplified (8-cycles). Final library concentrations were measured by Qubit, and
libraries were pooled in equimolar concentrations. The final pooled library was quantified by
quantitative PCR using the KAPA Library Quantification kit and the QuantStudio 6 Flex Real-Time
PCR System. Size distributions of the pooled submission were evaluated on 2100 Bioanalyzer
(Agilent Technologies). Pooled libraries were sequenced using 76 single-end or 76 paired-end cycles
on the HiSeq2000 or HiSeq4000 (Illumina) at the Sequencing Core Facility of the Department of
Genetics at MD Anderson Cancer Center.

2.5 Single-Cell Copy Number Data Analysis
Sequencing data was processed into a master FASTQ file using the CASAVA 1.8.1 pipeline
(Illumina Inc.) and then demultiplexed using an in-house perl script(16) into individual FASTQ files
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representing the sequencing reads from each single cell. Sequence reads were aligned to the NCBI
build 37 (HG19/NCBI37) using Bowtie2(134) and converted to sorted BAM files. Poorly mapped
reads (MQ<40) were filtered out using Samtools (0.1.19)(135). PCR duplicates were identified as
sequencing reads with the exact same starting position and were also removed from read counts via
an in-house Python script. Single cell copy numbers were calculated using the variable binning
method followed by the Circular Binary Segmentation (CBS)(145) as previously described(12, 125).
Sequencing reads were counted into 11,927 genomic bins with variable start and stop coordinates to
simulate mapping bias across the genomic positions, where the median genomic length spanned by
each bin is 220 kb. Loess normalization was used to correct for GC bias(125). Copy number
segmentation was performed using the CBS method(145) followed by MergeLevels(146) to join
adjacent segments with non-significant differences in segment ratios. The parameters used for CBS
segmentation was alpha=0.0001 and undo.prune=0.05 respectively. Default parameters were used
for performing MergeLevels, which successfully joined false positive detections of erroneous
chromosome breakpoints.

2.6 Single-Cell Copy Number Clonal Dynamics
Clonal subpopulations in single cell copy number data were defined using a hierarchical clustering
method as previously described(16). The optimal number of clusters was determined by the average
silhouette distance width. To construct the clustered heatmaps, the Euclidean distances were
calculated from a segmented copy number data matrix where each column represented one single cell
and each row contained the [log2(ratio+0.1)] transformed data of each segment. One-dimensional
hierarchical clustering with ‘ward.D2’ linkage was performed in R using the heatmap.3 function from
the ‘gplots’ package available on CRAN(147). Following identification of clonal subpopulations, the
consensus copy number profile of each subpopulation was calculated by using the consensus ratio of
each segment as the median ratios of all single cells within the subpopulation. Clonal lineage analysis
was performed on aneuploid single cells that had genome-wide copy number aberrations. The
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relative clonal frequencies of each subpopulations were calculated as the number cells that fell into
each specific sub-clusters divided by the total number of clonal cells. The tree structures of the
clonal subpopulations was inferred using the neighbor-joining (NJ) tree method in the ‘ape’
package(148). Clonal lineages were then analyzed with TimeScape(149) using the NJ tree structures
and the clonal frequencies across the treatment time points from the PROMIX trial.

2.7 Development of Novel Next-Generation Sequencing Methods
2.7.1 Preparation of Single-Nucleus Suspensions
Nuclei from frozen tumors were isolated using a NST/DAPI buffer (800 mL of NST [146 mM
NaCl, 10 mM Tris base at pH 7.8, 1 mM CaCl2, 21 mM MgCl2, 0.05% BSA, 0.2% Nonidet P-40]),
200 mL of 106 mM MgCl2, 10 mg of DAPI, and 5mM EDTA. The frozen tumors were dissociated
into nuclear suspensions by mincing with no.11 surgical scalpels in 1ml of NST-DAPI cytoplasmic
lysis buffer at 4C using ice blocks in a plastic Petri dish. Nuclear suspensions were filtered through
37-µm plastic mesh filters (Falcon). The final suspension was diluted to 1000 µL of 1 cell/50 nL
with 1x PBS and D-RNase free water (0.35× PBS in the final dilution). For the SKBR3 cell line, a 10
cm cell plate at ~100% confluence was tryspinized and washed two times with 1x PBS. The nuclei
were released and stained with DAPI/NST lysis buffer, re-pelleted, suspended in DAPI-NST, and
then filtered through a mesh filter. As with the tumor single-nucleus suspension, the final
suspension was diluted to 1000 µL of 1 cell/50 nL with 1x PBS and D-RNase free water.

2.7.2 Preparation of Single-Cell Suspensions
The single cell SK-BR-3 experiment was completed on the same day as the single-nucleus SK-BR-3
experiment and used the same passage of cells. A 50% confluent 10 cm plate of SKBR3 cells was
trypsinized, washed two times with 1× PBS, filtered, and stained with Hoechst 33342 and propidium
iodide (PI) to distinguish live/dead cells according to manufacturer’s recommendations
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(ThermoFisher). The whole-cell suspension was dispensed in the same manner as the nuclear
suspension (Figure 4).

Figure 4 – Microscopy of stained single whole cells and nuclei. Purified suspensions of single cells
and single nuclei from the MDA-MB436 breast cancer cell line were stained with DAPI (nuclei) or
Hoechst (cells) and imaged using fluorescence and brightfield microscopy at 40X magnification.
Although the majority of DAPI is excluded by the cell membrane in living cells, there is always a
small amount that permeates and shows low-level staining of the nucleus of live cells. However
these levels are much lower compared to the DAPI staining in the isolated nuclei (right panels).

2.7.3 Imaging QC of Nuclear and Cellular Suspensions
To ensure that the nuclear fractions did not have any evidence of cytoplasmic membranes, we
stained the nuclear fractions with Hoechst and Cytotracker Red for imaging at 40X on the Nikon
Eclipse fluorescent microscope. Similarly we stained cellular fractions with Hoechst and Cytotracker
Red to image the cytoplasm and nucleus. Z-stack images were collected in fluorescent channels, in

27

addition to brightfield imaging, and images were merged to observe the cytoplasm and nuclei of the
cell suspensions.

2.7.4 Nanogrid Single Cell/Nucleus Sequencing System
The ICELL8™ single cell nanogrid RNA sequencing system consists of three main components:
1) An ICELL8™ nanogrid chip manufactured in a square layout (72x72) in a 41 mm2
aluminum alloy with 5184 nanoliter wells (150nl) using standard manufacturing
processes(150). Each nanowell was preprinted with barcoded primers (UMIs) with poly(dT)
ends during manufacturing. This chip-based technology has been published previously in
targeted sequencing and real-time PCR applications(151, 152).
2) A multisample nanodispenser (MSND) that uses microsolenoid-control to precisely dispense
50 nL volumes into the nanowells.
3) An automated imaging system composed of an Olympus BX43 microscope fitted with a 4x
objective, a robotic stage and a CCD camera that is programmed to take images of all 5184
wells using a customized version of µManager open source software, followed by automated
image analysis software called CellSelect™ that is used to analyze acquired images and
identify single-cell or nuclei containing wells.
A more detailed technical description of the ICELL8 nanogrid single cell sequencing system and its
hardware components is provided elsewhere(153).

2.7.5 Nanodispensing of Nuclei and Cells
Disaggregated nuclear or cellular suspensions were diluted to 20 cells/µl in eight wells of a 384-well
plate (A1 through D2) and dispensed into the WaferGen ICELL8™ chip, resulting in a Poisson
distribution with about 30% of nanowells with single nuclei or cells. Poisson distribution of cells or
nuclei in the chip nanowells was achieved because each 50 nL dispense on average dispensed a single
cell when cells were at 20 cells/µl. Addressing every well of the ICELL8 chip took 12-15 min.
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Every nano-well contained an adapter sequence with a well Barcode (WB, 11nt), Unique Molecular
Identifier(43) (UMI, 10nt) and a 30-mer oligo-dT that was subsequently incorporated into the 3’ end
of the transcript during whole-transcriptome-amplification (WTA) using the Smart-Seq2(111)
chemistry.

2.7.6 Nanowell Imaging and Selection of Single Nuclei and Cells
Following cell dispensing, the microchip was centrifuged to collect cells in a single plane and the
nanogrid wells were automatically imaged using an Olympus BX43 fluorescent microscope with a
robotic stage. The image acquisition took about 6 min (3 min per fluorphore). After imaging, the
microchip was sealed, placed in freezing chambers, and stored at -80°C until reverse-transcription
(RT). Custom CellSelectTM software identified wells with single cells and filtered cells with no cells or
multiple cells based on multiple automatic and user-adjustable imaging parameters. The nanowells
with single cells or nuclei were then prioritized and the user could manually review images and
fluorescent channels to identify live cells or nuclei for selection. A file containing positional
information on identified candidate wells (dispense file) instructed the nanodispensor to deposit
reagents only in the selected wells for WTA.

2.7.7 3’ Reverse Transcription and PCR Amplification
Two versions of the RT chemistry were used in the study. Version 1 was used for method
development, wherein frozen chips were thawed, and 50nL of RT solution (88µL 5x RT buffer,
44µL 10mM RT dNTPs, 4.4µL 100 µM RT E5OLIGO, 57.2µL D-RNase-free water, and 26.4µL
200 U/µL RT enzyme) was deposited into each selected well via the nanodepositing system. For
chips with single nuclei, the 57.2µL D-RNase-free water was replaced with 52.8µL D-RNase-free
water and 4.4µL Triton X-100 to promote lysis of the cellular membrane. After RT, cDNA products
from selected wells were pooled together, purified, and underwent exonuclease I treatment (2µL 10×
exonuclease buffer, 1µL 20 U/µL exonuclease I) to remove excess, unannealed primers. The pooled
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barcoded cDNA libraries then underwent PCR amplification (5µL 10× amplification buffer, 1µL 50x
amplification dNTPs, 1µL amplification primer, 1µL amplification enzyme, 22µL D-RNAse-free
water) for 18 cycles for cells or 19 cycles for nuclei. The PCR products were purified with 0.6×
AMPure XP beads and eluted in 12µL D-RNase-free water. The size distribution of cDNA was
QCed using the Qubit dsDNA HS Fluorometric Assay and Agilent’s High Sensitivity DNA Chip on
the Bioanalyzer system.
Version 2 was used for the longitudinal TNBC samples from the PROMIX trial. Frozen
chips were thawed, and 50nL of RT solution (56µL 5M betaine, 24µL 25 mM dNTP mix, 3.2µL 1 M
MgCl2, 8.8µL 100 mM DTT, 61.9µL 5X SMARTScribeTM First-Strand Buffer, 33.3µL 2X SeqAmpTM
PCR Buffer, 4.0µL 100µm RT E5OLIGO, 8.8µL 10µM Amp Primer, 1.6µL 100% Triton X-100,
28.8µL SMARTScribeTM Reverse Transcriptase, and 9.6µL SeqAmpTM DNA Polymerase) was
deposited into each selected well. After RT, complementary DNA (cDNA) products from selected
wells were pooled together, purified, and underwent PCR amplification. The amplified product was
purified with 0.5x AMPure XP beads and eluted in 11µL D-RNase-free water. Eluted product was
quantified with Qubit dsDNA HS Fluorometric Assay and Agilent’s High Sensitivity DNA Chip.

2.7.8 Library Construction and Next-Generation Sequencing
The pooled cDNA was diluted to 0.2 ng/µL and used to construct Nextera XT (Illumina) DNA
libraries with i7 index primers following manufacturers instructions. The final libraries, containing
barcoded single-nuclei or single-cell transcriptomes, were sequenced at 100 paired-end cycles on the
HiSeq4000 system (Illumina). Data was processed using the CASAVA 1.8.1 pipeline (Illumina Inc.),
and sequence reads were converted to a master FASTQ files.

2.7.9 Bulk RNA Sequencing of Nuclei and Cells
Bulk RNA sequencing was used to compare the transcriptional profiles of nuclear and whole-cell
populations. RNA was extracted from nuclear and cell fractions isolated from four breast cancer cell
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lines (MDA-MB-436, BT-549, MDA-MB-231, T47D). One 10 cm dish at 60-85% confluence was
used for each biological replicate (three biological replicates per cell line) and was washed with 9mL
of 1x PBS (-/- for calcium and magnesium). Cells were then resuspended in 1 mL trypsin and 9 mL
cold PBS (1x, -/-). 60µL of the trypsinized cells were set aside to prepare slides for whole-cell
imaging and microscopy. The remainder of the cells was spun at 200 rcf for 5 minutes. The
supernatant was subsequently removed, and the cells were resuspended again in 2 mL PBS (1x, -/-).
One mL of the PBS cellular suspension was removed for whole-cell RNA extraction, spun at 100 rcf
for 5 minutes at 4C, and resuspended in 2 mL trizol. A 20G needle was used to break apart the
insoluble trizol pellets, and whole-cell RNA extraction was performed according the manufacturer’s
instructions (Fisher TR 118-100ML). The other mL of the PBS cellular suspension was removed for
nuclear RNA extraction, spun at 100 rcf for 5 minutes at 4°C, and resuspended in 1 mL DAPI/NST
with EDTA. The DAPI/NST solution was incubated at room temperature for 4 minutes, spun at
8000 rcf for 5 min at 4C, and resuspended in 1 mL DAPI/NST. After a final spin at 8000 rcf for 5
min at 4C, the nuclei were resuspended in 1 mL trizol. A 20G needle was used to break apart the
nuclear pellet, and an additional 1 mL of trizol was added to the suspension. Nuclear RNA
extraction was performed according the manufacturer’s instructions (Fisher TR 118-100ML).

2.8 RNA Sequencing Data Analysis
2.8.1 RNAseq QC and Data Processing
The master FASTQ file containing total reads was demultiplexed into individual FASTQ files with
each representing one single cell or one population of cells using a Perl script (Figure 5a).
Sequencing reads in each single FASTQ files were mapped to the human transcriptome using
bowtie2(154), and gene expression levels were summarized into expected count and transcripts per
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kilobase million (TPM) values using RSEM(155). Only uniquely mapped reads were used for
a

b

c

d

f
e

Figure 5 - Data processing and analysis workflow for single whole cell and single nuclei. (a)
Sequence reads are demultiplexed by well barcodes (WBC) and aligned to the human genome
reference assembly. (b) Quality control metrics are calculated and read counts are normalized by
library size and housekeeping genes, transformed to z-scores or TPM using RSEM. (c) Differentially
expressed genes are identified using SCDE and annotated for gene ontologies and pathways. (d)
Clustering and multivariate analysis is performed to identify groups of cells with similar
transcriptional profiles. (e) Copy number profiles are calculated from RNA profiles. (f) Gene
signature analysis and classification of breast cancer subtypes is performed.
analysis. A quality control step was performed on the tophat2(156)-aligned BAM files using
RSeQC(157) and Samtools (0.1.19)(135) to summarize distributions of reads that were mapped to
ribosomal RNA (rRNA), mitochondrial RNA (mtRNA), introns, coding sequence (CDS), 5’UTR,
3’UTR and 10 kb up-/down-stream of transcripts (Figure 5b). The number of UMIs for each gene
was counted by dropping reads that had duplicated UMIs using custom Perl scripts. However, we
did not include UMI assays in this study.
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2.8.2 Differential Gene Expression Analysis
We compared the gene expression in single nuclei to whole cells using a Bayesian method for singlecell differential expression (SCDE)(158) analysis, which fits individual error models for single cell
RNAseq data using a Bayesian approach based on a zero-inflated negative binomial model process
(Figure 5c). The differentially expressed genes were defined as false discovery rate (FDR) adjusted pvalue < 0.05 and |log2(fold change)| >=1. We removed genes that were detected with counts <10
in less than 30 cells. We applied an Empirical Bayes hierarchical model (EBSeq)(159) for population
RNAseq differential expression analysis at gene levels. The differentially expressed genes were
defined as those had Posterior Probability of being DE (PPDE) > 0.95 and |log2(fold change)|
>=1. Clustered heatmaps of gene expression were generated with R package ‘heatmap3’(17) based
on log2(count+1), log2(TPM+1) or z-scores (Figure 5d). Differentially expressed genes were
analyzed with Ingenuity IPA for pathway analysis and cellular organelle localization annotations. To
identify differentially expressed cancer genes in TNBC tumor cells, we combined the three
subpopulations of single nuclei that had aneuploid CNA profiles as tumor cell populations and
combined the predicted matched normal nuclei and normal nuclei from another patient as the
normal cell populations. We then performed differential gene expression analyses between the two
groups of single nuclei using MAST(160, 161). The differential genes were defined as having FDR
adjusted p-value < 0.05 and |log2 (fold change)| ≥1. Finally, differentially expressed cancer genes in
tumor cells were identified by intersecting the DE gene list with a T200 clinical gene panel and with a
40-gene TCGA breast cancer gene list.

2.8.3 Breast Cancer Subtype Prediction
We used the intrinsic gene centroids signature (PAM50)(162) to classify single cells and nuclei into 5
established intrinsic breast cancer molecular subtypes (normal-like, basal, luminal A, luminal B and
Her2 amplification) using ‘genefu’ package(163) with log2(TPM+1) data matrix. Single cells or
nuclei with low prediction confidence (< 0.7) are set as undefined. In a separate analysis, single
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nuclei were classified into 6 TNBC subtypes including 2 basal-like (BL1 and BL2), an
immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem–like (MSL), and a luminal
androgen receptor (LAR) subtype(11). The ER+ cells were excluded from TNBC subtype
prediction (Figure 5f).

2.8.4 Gene Set Variation Analysis
We applied single-sample gene set variation analysis (ssGSVA)(164) to determine the molecular
phenotypes of single cells and nuclei using log2(TPM+1) data (Figure 5f). We first obtained GSVA
scores for 189 oncogenic gene sets (MSiDB version 5.2)(165) for each single nuclei or whole-cell
sample, and then compare the nuclei enrichment scores to whole cells by using the R package
‘limma’(166). Differentially enriched gene sets were defined as FDR adjusted p-value < 0.05 and
|score difference|>= 0.1.

2.8.5 Cell Cycle Analysis of Single Nuclei
Cell cycle genes from the gene ontology set (version 5.2 MSiDB)(167-169) with annotations of “G1
phase of mitotic cell cycle” for G1 phase genes, “S phase of mitotic cell cycle” for S phase genes, “M
phase of mitotic cell cycle” for M phase genes were used. A G2 phase gene list that was previously
defined in synchronized HeLa cells was also used(170). We then defined the four cell phase (G1, S,
G2, M) scores as the average expression [log2(TPM + 1)] of curated cell cycle genes and defined the
cell cycle phase by hierarchical clustering of centered phase scores using R package ‘heatmap3’(17).

2.8.6 High-Dimensional Reduction Data Analysis
The normalized log2(count+1) matrix was centered and scaled to z-scores to perform principle
component analyses (PCA) using the ‘prcomp’ function in R (www.r-project.org). Genes that were
detected in fewer than 30 cells were excluded from the analysis. The first 5 components were
selected based on ‘elbow’ principle and the top 20 loading genes were sent for clustering using a
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shared nearest neighbor (SNN) modularity optimization based method(171). Then, marker genes for
each detected cluster were selected using the normalized log2(count+1) matrix with the ‘bimodal’
based gene expression analysis(172) that was built in the ‘FindAllMarkers’ function in the R package
‘Seurat’(173). The t-distribution Stochastic Neighbor Embedding (t-SNE)(174) method was applied
based on the pair-wise Euclidean distances of the log2(count+1) matrix. Hierarchical clustering with
‘ward.D2’ linkage and ‘Euclidean’ distance was performed on log2(count+1) matrix or z-scores using
R package ‘heatmap3’(17).

2.8.7 Copy Number Calculation from Single-Cell RNA Data
Single-cell and nucleus copy number was calculated from the log2(TPM+1) matrix using a ‘moving
average’ approach that was adapted from a previous study(47) (Figure 5e). We used the
log2(TPM+1) values as gene expression values and we further scaled the total expression of all cells
to 100,000 to normalize gene expression within each single cell to comparable scales and to avoid
floating the variance among highly expressed genes. We sorted the analyzed genes by their genomic
coordinates, which were annotated by a UCSC gene list containing a total of 23,346 genes. We
excluded genes that had expression values < 0.15 on average, and ended up with ~3000 genes across
the genome and ~130 genes per chromosome on average (except the Y chromosome, which had
only one or two genes). To define the copy number baseline, we also sequenced a set of 380 normal
breast tissue single cells, and took their average expression of each gene as the normal copy number
base line. We normalized single-cell gene expression to this baseline in order to obtain a relative gene
expression for each gene location. To mitigate the bias caused by extreme gene expression levels, we
replaced the relative gene expression values that were > 3 with 3 and relative expressions that were <
-3 with -3. We then obtained a ‘moving average’ of adjacent 50-gene relative expression values to
represent the log2(copy number ratio) of the genomic location. We normalized the log2(copy number
ratio) to their mean values for each cell to center around zeros. Lastly, we performed hierarchical
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clustering(17) of all tested single cell CNAs with the normal breast tissue cells to identify aneuploid
tumor and normal diploid cell populations.

2.8.8 Normal Cell Type Prediction from Single-Nucleus RNA Data
Prediction of known normal cell types in the clonal extinction post-treatment tumors was performed
using a semi-supervised approach. We first classified immune cell types using established markers: T
cells (CD4|CD8A|CD8B), B cells (CD19|CD20) or other immune cells (CD45). For the remaining
cell types we performed a decision tree using Gini coefficients to evaluate the variability of known
cell type markers across all the remaining cells. Larger Gini coefficients indicated stronger
unevenness of the marker gene expression across the remaining cell populations, and therefore the
cell type with the largest Gini coefficient was determined first. The remaining cell types with smaller
coefficients were identified subsequently in an iterative process. The markers for the remaining cell
type classification in sequential included: fibroblasts (ACTA|CAV1|FAP|FN1), luminal epithelial
cells (CK8|CK18), adipocytes (ADIPOR1/2), basal epithelial cells (CK5|CK14) and endothelial
cells (PECAM1|CD34). We used the gene expression [log(TPM/10+1)] cutoff=1 to determine
whether a cell marker was expressed in a single cell. In our datasets, we observed a subset of cells
that were co-expressed both fibroblasts and epithelial cells markers. Since ‘fibroblast’ cells were
defined before epithelial cells, we reclassified certain ‘fibroblast’ cells as epithelial cells if they
expressed higher levels of epithelial markers on average.

2.8.9 Survival Analysis in Extended Patient Cohorts
To determine whether the chemoresistance-associated gene signatures were associated with patient
survival, we obtained the METABRIC dataset (175, 176) with mRNA gene microarray expression
data and long term clinical follow-up data. We analyzed a total of N=412 breast cancer patients that
received chemotherapy. To test the association of selected gene sets with patient survival, we first
performed gene set variation analysis (164) and stratified patients into low enrichment (ssGSVA
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score ≤ -0.1) and high enrichment (ssGSVA core ≥ 0.1) groups. We then performed a Cox
proportional hazard regression of survival month and survival status over gene set enrichment status
using the R ‘survival’ package (Therneau 2015) and the log-rank test p-values were used to determine
significance.

2.9.0 Integration of Single-Cell Copy Number Data with SNV Mutations
To integrate single cell copy number with the bulk mutation data, we used Samtools (0.1.19) (135) to
perform ‘mpileup’ of sparse single cell copy number reads and quantified the number of variant reads
at specific mutation sites that were detected by exome sequencing. Mutation sites with ≥ 1 variant
read counts in at least one cell were called as mutated sites. Mutations in single cells were then
mapped to clonal subpopulations in maximum parsimony trees constructed from the single cell copy
number data. With this approach, a subset of clonal mutations were successfully mapped to the
truncal lineages of the copy number trees, however the limited coverage at subclonal mutation sites
did not permit accurate mapping to the subclonal lineages.

2.9.1 Integration of DNA Mutations and RNA Single-Cell Data
Since the single nuclei RNA expression data had coverage only at the 3’ ends, we mapped all exome
mutation sites to the last exons of genes to identify a subset of mutations with these criteria. We
used Samtools (0.1.19) (135) ‘mpileup’ to obtain sparse 3’ single cell RNA sequencing read counts for
mutations detected in the last exons of genes. Mutation sites with ≥ 1 read count coverage in the
RNA data that matched the mutation variant base were considered as positive for having the
expressed mutation, while sites with ≥ 1 read count coverage and only reference bases were
considered as negative for the expressed mutation. Sites with no read count data in samples were
indicated as ‘low coverage’ for detecting the expressed mutation.

2.9.2 Identification of Primed Cells by Integrating Single-Cell CNA and RNA Data
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We identified ‘primed’ cells in the pre-treatment tumor samples that expressed a subset of the
chemoresistant genes by integration of single cell CNA data with single cell RNA data. Due to the
sparseness of the single cell RNA data, we performed imputation using Single Cell Analysis Via
Expression Recovery (SAVER) (177) to improve copy number estimations. Next, we identified the
CNAs associated with resistance in the single cell DNA copy number profiles that expanded in the
resistant clones from the persistence patients. To find the pre-existing single cells that had resistant
CNA genotypes, we clustered all pre-treatment single cells with post-treatment single cells using
hierarchical clustering with the calculated RNA copy number profiles. Single cells with resistance
associated CNAs that clustered together were defined as having a resistant genotype, whereas pretreatment single cells that did not have resistance associated CNAs were defined as having a sensitive
genotype. We next obtained a restricted list of significant top variable genes (N<50 genes) by
comparing the transcriptional profiles of the post-treatment resistant cells (those that had both
resistant genotypes and phenotypes) to pre-treatment nonresistant cells (those that did not have
resistant genotypes or phenotypes) using MAST (FDR adjusted p < 0.05; |log2(fold change)| ≥
1.58) (160). Next, we performed random forest regression with the R ‘randomForest’ package (178)
on 70% of the data using the top variable genes followed by prediction of resistance/sensitive
classification for all single cells within each tumor. We defined the predicted probability of classifying
a resistant single cell to be the resistance expression score of each cell. To determine the cutoff of the
resistance expression score and define the primed cells, we calculated the cutoff score that separated
pre-treatment cells within each tumor into two groups using the least square method and took the
median values across the 4 patients as the universal cutoff (cutoff=0.172). We manually set the
resistance cutoff as 0.6 to account for RNA dropout noise in the single cell RNA data. As such,
single cells that had a resistance expression score >=0.6 were defined as resistant cells, and single
cells that had resistance expression scores between 0.172 and 0.6 were defined as primed cells.
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CHAPTER 3: NANOGRID SINGLE-NUCLEUS RNA SEQUENCING REVEALS
PHENOTYPIC DIVERSITY IN BREAST CANCER
[Note: This chapter is based on published material from Gao and Kim et al. 2017 (Gao, R and Kim,
C. et al. Nanogrid Single-Nucleus RNA Sequencing Reveals Phenotypic Diversity in Breast Cancer
Nat Commun 8, doi:doi:10.1038/s41467-017-00244-w, 2017). Nat Commun articles are published
under a CC BY license (Creative Commons Attribution 4.0 International License), which establishes
that authors retain copyright in their articles.]
3.1 Introduction and Rationale
Single-cell RNA sequencing has provided new insights into cancer progression by resolving complex
cell types(42, 47, 179), developmental hierarchies(42, 47, 180) and phenotypic plasticity(44, 46).
However, initial methods were limited by low-throughput, high costs and extensive technical errors,
which inhibited their broad application in cancer research(128, 181, 182). Recent technological
innovations using microwells(108, 183, 184) and microdroplet encapsulation(110, 112) have increased
the throughput of single cell RNAseq to thousands of cells and greatly reduced associated costs.
However, high-throughput methods do not enable imaging or selection of single cells, leading to high
doublet error rates and the inclusion of many unwanted cells, such as dead cells(128). Furthermore,
the ability to sequence RNA in nuclei instead of whole cells on these platforms has not been
demonstrated.
A second major challenge for single-cell RNA sequencing in cancer research is that most
methods require fresh tissue to be dissociated into single cell suspensions for analysis(185). This is
logistically challenging and problematic in cancer research, because the majority of archival tissue
samples have previously been flash-frozen and stored in cryobanks, a process that ruptures the cell
membranes. Nevertheless, previous work has shown that nuclear membranes remain intact during
freeze-thaw cycles, and that single nuclei can be isolated from frozen tissues(186), consequently
permitting the preparation of nuclear suspensions(12, 17, 18) and construction of nuclear cDNA
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libraries. Neuroscientists have also shown that RNA sequencing of single nuclei is feasible and
highly representative of transcriptional profiles from cells, when fresh tissues are dissociated(109,
186-188) and even when postmortem brain tissue stored long-term at -80ºC is used(186). This is in
contrast to whole brain cells, where use of proteases for whole cell dissociation has been shown to
activate the crucial immediate early genes(189) and confound RNAseq results. However, to date, no
one has investigated the transcriptional profiles of single tumor nuclei, to determine if they are
representative of whole tumor cells.
To address these limitations, we developed a novel nanogrid platform and microfluidic
depositing system that enables imaging, selection and sequencing of thousands of single cells or
nuclei in parallel. We applied this nanogrid single-nucleus RNA sequencing (SNRS) system to
compare the transcriptional profiles of cancer cells and nuclei in cell lines and further applied this
method to study phenotypic diversity and subpopulations in a frozen tumor sample from a TNBC
patient. We subsequently used this system to evaluate the phenotypic evolution of TNBC in
response to chemotherapy.

3.2 Results
3.2.1 Concordance of Bulk Nuclei and Cells from Cell Lines
Prior to single cell analysis, we investigated whether the transcriptional profiles of bulk cells and
nuclear fractions are concordant in breast cancer cell lines. We performed RNAseq of nuclear and
cellular fractions isolated from millions of cells from 4 breast cancer cell lines, including three triplenegative subtypes (BT549, MDA-MB231, MDA-MB-436) and an ER+/PR+ subtype (T47D).
Nuclear fractions were purified from cellular suspensions using a detergent to lyse the plasma
membrane, followed by three rounds of purification to eliminate residual cytoplasmic RNA. The
nuclear suspensions were imaged in bright field and fluorescence using DAPI to ensure that the
cellular membrane and cytoplasm were no longer present. RNAseq was performed on the nuclear
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Figure 6 – Bulk sequencing metrics of whole cells versus nuclei. (a) Scatter plots of gene expression
[log2(counts+1)] from bulk cellular and nuclear fractions isolated from four breast cancer cell lines.
Significant differentially expressed genes are highlighted in red and Pearson correlations are
indicated. (b) Gene expression heatmap of 40 breast cancer genes identified in TCGA across three
biological replicates of bulk cell and nuclei factions from the four breast cancer cell lines.
and cellular fractions from each cell line at 20 million reads per sample, resulting in 50% of the reads
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mapping to the CDS regions and 15-16K gene coverage for each cell line. Correlations in gene
expression levels between the nuclear and cellular suspensions were very high (rs > 0.9), with only 338 discordant genes in each sample (Figure 6a). In total, BT549 showed 13/15699 discordant genes,
while MDA-MB231 showed only 3/15592 discordant genes, MDA-MB436 showed 4/16479
discordant genes, and T47D showed 6/16314 discordant genes between cells and nuclei.
Importantly, most genes had differences in expression levels, rather than having a complete absence
of expression in the cells or nuclei. However, EIF3CL was only detected in BT549 whole cells, and
was not detected in the nuclei. We speculate that is the result of rapid transportation between cellular
compartments, since the sequencing depth was sufficiently high in both samples to rule out falsenegatives. Notably, 6 differentially expressed genes were read-through transcripts (Figure 6a).
We also examined the gene expression levels for a targeted set of 40 breast cancer genes that were
previously reported to be frequently deregulated in TCGA(13). These data showed only minor
variations between cells and nuclei that were not statistically significant (FDR adjusted p-value >=
0.05 or |log2(fold change)| < 1) across three biological replicates in each of the 4 cell lines (Figure
6b). Collectively, these experiments suggested that the transcriptional profiles of bulk nuclear RNA
are highly representative of cellular RNA in breast cancer cell lines.

3.2.2 Nanogrid Single Nucleus RNA Sequencing Method
We developed a high-throughput nanogrid single nucleus RNA sequencing (SNRS) approach called
the ICELL8 system (Wafergen, Inc) (Figure 7). The nanogrid system consists of three main
components: 1) an alloy nanogrid with 5184 nanowells, 2) a nanodispensing system and 3) an
automated imaging system. First, single cell or single nucleus suspensions are prepared from cell
lines or frozen tissues and stained with propidium iodide (PI) and Hoechst (cells) or stained with
DAPI (nuclei). The suspensions are then diluted to 1 cell or nucleus per 50nL and dispensed into the
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Figure 7 – Wafergen sequencing pipeline. (a) Nuclear or cellular suspensions are prepared and
stained with DAPI (nuclei) or Hoechst and Propidium Iodide (cells) for nanodispensing into the
5184 wells in the nanogrid. Each nanowell is 400-600 µm, and the well depth range is 950 µm – 2.2
mm. (b) The nanowells are imaged using automated scanning fluorescent microscopy and
approximately 1800 wells containing single nuclei or cells are selected, while nanowells containing
multiple cells, no cells or dead cells are excluded. (c) In the selected nanowells, the nanodispensor
deposits lysis buffer and WTA reagents to perform reverse transcription of mRNA to cDNA using
SCRB-Seq chemistry. This process also adds a UMI, well barcode and P5 adapter sequence to the
(A)n tail. N represents A, C, G, or T; B represents C, G, or T; and V represents A, C, or G. (d) The
barcoded cDNA with adapter sequences is pooled into a single reaction. (e) Nextera tagmentation is
performed followed by PCR amplification to generate sequencing libraries with Illumina I7 indexes.
(f) Next-generation sequencing is performed on the pooled libraries, after which the individual cell
data is demultiplexed using the well barcodes

nanogrid resulting in a Poisson distribution of cell occupancies across the 5184 nanowells with
~1800 wells that are expected to have single cells or nuclei (Figure 7a, Figure 8). Each well in the
nanogrid has a unique 11bp pre-printed well barcode (WBC) that also contains an oligo dT sequence,
a 10bp unique molecular identifier (UMI) and a P5 Illumina adapter sequence. After the cells or
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Figure 8 – Sequencing library structure of Wafergen libraries. 3’ Single cell RNA sequencing is
performed by hybridization of the polyA mRNA tail to an oligo dT30 adapter with a 11bp well
barcode and 10bp UMI that is pre-printed in each nanowell. Single cells or nuclei undergo reversetranscription using template switching and extension, followed by full-length cDNA amplification. A
one-sided tagmentation reaction is then used to add a Nextera transposase adapter to the 5’ end (the
other strand is omitted for illustrative purposes). PCR is performed using the nextera P5 primer and
i7 index primer to extend the adapter sequences and enrich the library concentrations. The final
sequencing reaction involves 3 sequencing primers to read the WBC and UMI (read1), the 3’ RNA
sequence (read 2) and the i7 nextera sample index (read3). In this figure N represents A, C, G, or T;
B represents C, G, or T; and V represents A, C, or G. Dotted lines indicate where the first nucleotide
hybridizations occur.
nuclei are dispensed, automated imaging is performed within 10 minutes using a fluorescent
microscope with a robotic stage to image all 5184 wells (Figure 7b). The software automatically
identifies nanowells containing single cells or nuclei and excludes wells with doublets or no cells.
The user can then choose to manually select a subset of the prioritized cells based on the
morphology parameters, PI, Hoechst or DAPI staining. Only wells with live cells (PI -, Hoechst +)
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or intact nuclei (DAPI+) are selected for depositing reagents for lysis and whole-transcriptomeamplification (WTA) (Figure 7b). The WTA reaction is performed using SCRB-Seq(190), which uses
template-switching to select polyadenylated RNA and incorporate a P5 adapter sequence along with
the WBC and UMI into the 3’ end of each RNA molecule (Figure 7c). A second adapter is added to
the 5’ end (RT-E5OLIGO) by template switching for second strand synthesis and subsequent PCR
enrichment. The nanogrid is then inverted and all of the barcoded cell libraries are pooled together
into a single reaction for PCR amplification followed by QC for size distributions (Figure 7d). The
cDNA is then used to generate Illumina sequencing libraries with one-sided tagmentation and PCR
amplification (Figure 7e). The pooled libraries are sequenced on the Illumina system, and individual
FASTQ files are demultiplexed using the WBC identifiers for downstream data processing and
analysis (Figure 7f).

3.2.3 Single Nuclei and Cell Concordance in a Cancer Cell Line
To determine if the transcriptional profiles of single nuclei were representative of whole-cells, we
applied nanogrid SNRS to isolate and sequence nuclei and cells from an isogenic Her2+ breast
cancer cell line (SK-BR-3) (Figure 9). Nuclear and cellular suspensions were prepared and stained
with a nuclear stain (Hoechst) and cytoplasmic stain (cytotracker) to confirm that the cytoplasmic
membrane was no longer intact in the nuclear suspensions (Figure 9a). We subsequently stained the
nuclear suspensions with DAPI and the cellular suspensions with PI and Hoechst and dispensed
single cells into the nanogrid for automated imaging (Figure 9b). In total, we selected 525 single
nuclei and 525 live cells in the nanogrids for sequencing (Figure 9c).
To understand global expression differences in the data, we computed a number of metrics
for the single cell and nuclei datasets (Figure 9d). On average, we sequenced 1.3 million reads per
nucleus or cell, achieving a coverage of 4600-5500 genes and average unique molecular index (UMI)
count of 34,690 (±12,609 S.D.) for cells and 34,540 (± 10,570 S.D.) for nuclei. Single cells or nuclei
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with poor metrics were filtered, resulting in final datasets of 485 nuclei and 424 whole cells. Although
the difference in variance for most distributions was determined to be significant by KolmogorovSmirnov test (P < 0.05) due to large numbers of nuclei in each distribution, most metrics, including
mapped read fractions, 5’ UTR tags, 3’ UTR tags, rRNA reads and gene coverage showed very low
percent changes (2-5%) between nuclei and cells. However, we did observe an 8.5% increase in

a

b

c

d

Figure 9 – Microscopy, nanowell selection, and metrics for single whole cells and nuclei. (a) Nuclear
suspensions were stained with DAPI (blue) and cytotracker (red), while cellular suspensions were
stained with Hoechst (blue) and cytotracker (red) for fluorescent microscopic imaging at 40X
magnification to visualize the nucleus and cytoplasm. (b) Nanodispensed nuclei and cells were
imaged in nanowells using DAPI, or Hoechst and PI (c) Nanogrid maps of cells or nuclei that were
selected for RNA sequencing. (d) Sequence data metrics were calculated for single nuclei and single
cells from the SK-BR-3 breast cancer cell line.
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intron tags and 9.2% decrease in CDS tags in the single nuclei data, which is consistent with the
dogma that nuclei contain unprocessed pre-mRNA that have not yet undergone splicing and export
from the nucleus(191, 192). To compare our data to another platform, we performed Drop-Seq
analysis of SK-BR-3 cells and compared the sequencing metrics to downsampled Nanogrid RNA
data (Table 1). These data revealed similar per cell gene detection rates but higher UMI counts per
cell on the Nanogrid
platform.
Supplementary
Table 3- Comparison of Sequencing Metrics of Nanogrid
SNRS to Drop-seq
Platforms

Drop-seq

Nanogrid*

median total reads per cell

90,732

90,732

number of cells sequenced

8,128

525

median mapping rates per cell

29.00%

68.72%

median mapped reads per cell

26,312

62,354

median CDS reads/tags fractions

30.60%

72.26%

median Intron reads/tags fractions

6.00%

1.33%

median gene covered per cell

2,714

2,349

median UMIs per cell

16,414

25,061

*data were downsampled from original sequenced fastq files.

Table 1 - Sequencing and QC metrics for single cells that were profiled by nanogrid SNRS and
Drop-seq from the SK-BR-3 cell line. To perform a fair comparison the Nanogrid data was
downsampled to 90,732 reads per cell before metrics were calculated.
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Gene$ID
ANKRD20A9P
ARHGEF26FAS1
ATP6V0A2
BRIP1
C12orf65
C21orf62
CA5B
CBFA2T2
CCDC142
CEACAM22P
CEP104
CMBL
CNNM3
CRX
CYP4V2
DCAF10
DCUN1D2
FAM116A
DFFB
DMC1
ENTPD4
EPHA10
ERVVF1
EXD1
FAM126B
FAM74A1
FBLIM1
FBXO27
FLJ42102
FMN1
GFOD2
GGA2
GNE
GREB1
GRIPAP1
HNRNPA1P10
IGF2R
IL17RD
IRF1
KBTBD12
KDELC2
L1TD1
LAIR1
LINC00294
LINC00410
C14orf23
LOC100190986
LOC643406
LYZ
MAB21L3
MAP1LC3C
MAP7D3
MBOAT1
MEFV
MTFMT
LOC90834
LOC731424
LOC728558
LOC147670
LOC145663
LOC100190938
LOC642236
NLRP12
NPIPL3
NT5DC3
NUAK2
NXN
ORAI2
OTUD6A
P2RX5FTAX1BP3
PDDC1
PDE6A
PGM2L1
PGM5P2
PPP1R3B
PRR11
PSTPIP2
RBMS2
RPS6KA3
RRP7B
KIAA0226
RUNDC1
SCAI
SCD5
SERPINB9
SGSM1
SKA1
MCART1
SLC7A5P2
SPRED1
STAC2
FAM40B
STYX
TACC2
TADA2B
TAF8
TBXA2R
TLCD2
TNFAIP8L1
TSIX
UCKL1FAS1
UTP3
VPS53
VSIG1
VSTM4
WDR45
WNT7B
XIST
ZC3H12D
ZFYVE19
ZKSCAN3
ZMAT3
ZNF124
ZNF264
ZNF347
ZNF490
ZNF526
ZNF793
ZNF805
ZNF814
ZSCAN22

FoldChange
2.0
2.8
2.8
2.1
2.2
2.8
2.6
2.7
2.2
3.2
2.1
2.4
2.6
2.1
2.8
2.0
2.0
2.2
2.3
3.2
2.4
3.1
2.8
2.7
2.5
2.9
2.1
2.4
2.5
2.1
3.0
2.0
2.5
2.4
2.3
3.1
2.1
2.4
2.5
2.9
2.0
3.3
3.0
2.2
5.1
2.6
4.0
2.4
2.6
2.9
2.2
2.3
2.4
3.1
2.1
3.9
3.4
3.0
3.0
2.5
2.5
2.4
2.9
3.4
2.5
2.9
2.4
2.6
2.1
2.4
2.1
2.4
2.0
2.1
3.2
2.2
2.2
2.2
2.3
3.0
2.0
2.2
2.3
3.4
2.3
3.3
2.1
2.3
2.9
2.5
3.1
2.4
2.1
3.2
2.5
2.0
2.6
2.6
2.9
2.6
3.2
2.2
2.2
3.2
3.3
2.2
2.4
2.1
3.1
2.6
2.6
2.3
2.3
2.6
2.5
2.5
2.2
2.6
2.8
2.7
2.7

Entrez$Gene$Name
ankyrin1repeat1domain1201family1member1A9,1pseudogene
ARHGEF261antisense1RNA11
ATPase1H+1transporting1V01subunit1a2
BRCA11interacting1protein1CFterminal1helicase11
chromosome1121open1reading1frame165
chromosome1211open1reading1frame162
carbonic1anhydrase15B
CBFA2/RUNX11translocation1partner12
coiledFcoil1domain1containing1142
carcinoembryonic1antigen1related1cell1adhesion1molecule122,1pseudogene
centrosomal1protein1104
carboxymethylenebutenolidase1homolog1(Pseudomonas)
cyclin1and1CBS1domain1divalent1metal1cation1transport1mediator13
coneFrod1homeobox
cytochrome1P4501family141subfamily1V1member12
DDB11and1CUL41associated1factor110
defective1in1cullin1neddylation111domain1containing12
DENN1domain1containing16A
DNA1fragmentation1factor1subunit1beta
DNA1meiotic1recombinase11
ectonucleoside1triphosphate1diphosphohydrolase14
EPH1receptor1A10
endogenous1retrovirus1group1V1member11
exonuclease13'F5'1domain1containing11
family1with1sequence1similarity11261member1B
family1with1sequence1similarity1741member1A1
filamin1binding1LIM1protein11
FFbox1protein127
uncharacterized1LOC399923
formin11
glucoseFfructose1oxidoreductase1domain1containing12
golgi1associated,1gamma1adaptin1ear1containing,1ARF1binding1protein12
glucosamine1(UDPFNFacetyl)F2Fepimerase/NFacetylmannosamine1kinase
growth1regulation1by1estrogen1in1breast1cancer11
GRIP11associated1protein11
heterogeneous1nuclear1ribonucleoprotein1A11pseudogene110
insulin1like1growth1factor121receptor
interleukin1171receptor1D
interferon1regulatory1factor11
kelch1repeat1and1BTB1domain1containing112
KDEL1motif1containing12
LINEF11type1transposase1domain1containing11
leukocyte1associated1immunoglobulin1like1receptor11
long1intergenic1nonFprotein1coding1RNA1294
long1intergenic1nonFprotein1coding1RNA1410
long1intergenic1nonFprotein1coding1RNA11551
uncharacterized1LOC100190986
uncharacterized1LOC643406
lysozyme
mabF211like13
microtubule1associated1protein111light1chain131gamma
MAP71domain1containing13
membrane1bound1OFacyltransferase1domain1containing11
Mediterranean1fever
mitochondrial1methionylFtRNA1formyltransferase
NA
NA
NA
NA
NA
NA
NA
NLR1family,1pyrin1domain1containing112
nuclear1pore1complex1interacting1protein1family1member1B3
5'Fnucleotidase1domain1containing13
NUAK1family1kinase12
nucleoredoxin
ORAI1calcium1releaseFactivated1calcium1modulator12
OTU1deubiquitinase16A
P2RX5FTAX1BP31readthrough1(NMD1candidate)
Parkinson1disease171domain1containing11
phosphodiesterase16A
phosphoglucomutase12Flike11
phosphoglucomutase151pseudogene12
protein1phosphatase111regulatory1subunit13B
proline1rich111
prolineFserineFthreonine1phosphatase1interacting1protein12
RNA1binding1motif1single1stranded1interacting1protein12
ribosomal1protein1S61kinase1A3
ribosomal1RNA1processing171homolog1B,1pseudogene
RUN1and1cysteine1rich1domain1containing1beclin111interacting1protein
RUN1domain1containing11
suppressor1of1cancer1cell1invasion
stearoylFCoA1desaturase15
serpin1family1B1member19
small1G1protein1signaling1modulator11
spindle1and1kinetochore1associated1complex1subunit11
solute1carrier1family1251member151
solute1carrier1family171member151pseudogene12
sprouty1related1EVH11domain1containing11
SH31and1cysteine1rich1domain12
striatin1interacting1protein12
serine/threonine/tyrosine1interacting1protein
transforming1acidic1coiledFcoil1containing1protein12
transcriptional1adaptor12B
TATAFbox1binding1protein1associated1factor18
thromboxane1A21receptor
TLC1domain1containing12
TNF1alpha1induced1protein181like11
TSIX1transcript,1XIST1antisense1RNA
UCKL11antisense1RNA11
UTP3,1small1subunit1processome1component1homolog1(S.1cerevisiae)
VPS53,1GARP1complex1subunit
VFset1and1immunoglobulin1domain1containing11
VFset1and1transmembrane1domain1containing14
WD1repeat1domain145
Wnt1family1member17B
X1inactive1specific1transcript1(nonFprotein1coding)
zinc1finger1CCCHFtype1containing112D
zinc1finger1FYVEFtype1containing119
zinc1finger1with1KRAB1and1SCAN1domains13
zinc1finger1matrinFtype13
zinc1finger1protein1124
zinc1finger1protein1264
zinc1finger1protein1347
zinc1finger1protein1490
zinc1finger1protein1526
zinc1finger1protein1793
zinc1finger1protein1805
zinc1finger1protein1814
zinc1finger1and1SCAN1domain1containing122

cellular$localization
Other
Other
Cytoplasm
Nucleus
Other
Other
Cytoplasm
Nucleus
Other
Other
Cytoplasm
Cytoplasm
Other
Nucleus
Cytoplasm
Other
Other
Cytoplasm
Nucleus
Nucleus
Cytoplasm
Plasma1Membrane
Other
Other
Other
Other
Plasma1Membrane
Other
Other
Nucleus
Extracellular1Space
Cytoplasm
Cytoplasm
Cytoplasm
Plasma1Membrane
Other
Plasma1Membrane
Cytoplasm
Nucleus
Other
Other
Other
Plasma1Membrane
Other
Other
Other
Other
Other
Extracellular1Space
Other
Cytoplasm
Cytoplasm
Cytoplasm
Nucleus
Cytoplasm
NA
NA
NA
NA
NA
NA
NA
Cytoplasm
Other
Other
Other
Nucleus
Plasma1Membrane
Other
Other
Cytoplasm
Plasma1Membrane
Cytoplasm
Other
Cytoplasm
Other
Cytoplasm
Nucleus
Cytoplasm
Other
Cytoplasm
Other
Nucleus
Cytoplasm
Cytoplasm
Nucleus
Nucleus
Cytoplasm
Other
Plasma1Membrane
Other
Cytoplasm
Cytoplasm
Nucleus
Nucleus
Nucleus
Plasma1Membrane
Other
Cytoplasm
Nucleus
Other
Nucleus
Cytoplasm
Plasma1Membrane
Other
Other
Extracellular1Space
Nucleus
Cytoplasm
Cytoplasm
Nucleus
Nucleus
Nucleus
Nucleus
Nucleus
Nucleus
Other
Other
Other
Other
Nucleus

ST1.1$=$Genes$Upregulated$in$SK=BR=3$Nuclei$Compared$to$Cells
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gene$class
other
other
transporter
enzyme
other
other
enzyme
transcription1regulator
other
other
other
enzyme
other
transcription1regulator
enzyme
other
other
other
enzyme
enzyme
enzyme
transmembrane1receptor
other
other
other
other
other
other
other
other
enzyme
transporter
kinase
other
other
other
transmembrane1receptor
other
transcription1regulator
other
other
other
transmembrane1receptor
other
other
other
other
other
enzyme
other
other
other
other
other
enzyme
NA
NA
NA
NA
NA
NA
NA
other
other
other
kinase
enzyme
other
peptidase
other
other
enzyme
enzyme
other
other
other
other
other
kinase
other
other
other
transcription1regulator
enzyme
other
other
other
other
other
other
other
other
phosphatase
other
other
transcription1regulator
GFprotein1coupled1receptor
other
other
other
other
other
other
other
other
other
other
other
other
other
transcription1regulator
other
other
other
other
other
other
other
other
other
transcription1regulator

Gene$ID
FoldChange
PTS
AP2S1
ARF4
ALG14
ASNS
BOLA3
CD9
CKS1B
CETN2
C11orf73
COMMD3
COPS4
CNIH
C7orf44
DAZAP2
DRAM2
ESD
EIF5A
FOS
GABARAPL2
GTF2IP1
GNPDA1
GSTM4
CGA
H3F3AP4
HIGD1A
HAT1
IGFL1
ID1
ID3
ITGB3BP
JKAMP
LAMTOR1
MAD2L1
MEMO1
MT1X
MGST1
BRP44
MRPL39
MRPS14
MRPS23
LOC440354
LOC541471
LOC550643
NDUFAF4
NIT2
NUTF2
C20orf111
PDZD11
PRDX3
PIGU
PHLDA2
POLR2G
POLR2K
PFDN1
PPP6C
PLP2
RPA3
RPL21
SAMM50
C19orf42
TAX1BP3
TXNDC12
TMX2
TMEM106C
TMEM14A
TMEM18
TMEM99
TSFM
UBE2T
VPS25
VDAC3
WDR83OS
WDYHV1
ZNF706

$2.3
$2.2
$2.1
$2.5
$2.2
$2.6
$2.3
$2.4
$2.1
$2.0
$2.3
$2.0
$2.3
$2.5
$2.0
$2.5
$2.3
$2.0
$2.1
$2.5
$5.3
$2.2
$2.0
$2.1
$2.7
$2.1
$2.1
$3.6
$3.1
$2.0
$2.2
$2.9
$2.0
$2.1
$2.3
$2.2
$2.0
$2.6
$2.1
$2.2
$2.1
$2.1
$2.1
$2.0
$2.2
$2.2
$2.0
$2.2
$2.5
$2.3
$2.3
$2.9
$2.0
$2.5
$2.2
$2.0
$2.5
$2.0
$2.7
$2.2
$2.2
$2.6
$2.3
$2.2
$2.5
$3.6
$2.3
$2.6
$2.5
$2.0
$2.6
$2.0
$2.1
$2.5
$2.0

Entrez$Gene$Name
cellular$localization
6$pyruvoyltetrahydropterin7synthase
Cytoplasm
adaptor7related7protein7complex727sigma717subunit
Cytoplasm
ADP7ribosylation7factor74
Cytoplasm
ALG14,7UDP$N$acetylglucosaminyltransferase7subunit
Cytoplasm
asparagine7synthetase7(glutamine$hydrolyzing)
Cytoplasm
bolA7family7member73
Other
CD97molecule
Plasma7Membrane
CDC287protein7kinase7regulatory7subunit71B
Other
centrin72
Nucleus
chromosome7117open7reading7frame773
Cytoplasm
COMM7domain7containing73
Other
COP97signalosome7subunit74
Cytoplasm
cornichon7family7AMPA7receptor7auxiliary7protein71
Plasma7Membrane
cytochrome7c7oxidase7assembly7factor717homolog
Cytoplasm
DAZ7associated7protein72
Nucleus
DNA7damage7regulated7autophagy7modulator72
Cytoplasm
esterase7D
Cytoplasm
eukaryotic7translation7initiation7factor75A
Cytoplasm
FBJ7murine7osteosarcoma7viral7oncogene7homolog
Nucleus
GABA7type7A7receptor7associated7protein7like72
Cytoplasm
general7transcription7factor7IIi7pseudogene71
Other
glucosamine$6$phosphate7deaminase71
Cytoplasm
glutathione7S$transferase7mu74
Cytoplasm
glycoprotein7hormones,7alpha7polypeptide
Extracellular7Space
H37histone,7family73A,7pseudogene74
Other
HIG17hypoxia7inducible7domain7family7member71A
Cytoplasm
histone7acetyltransferase71
Nucleus
IGF7like7family7member71
Extracellular7Space
inhibitor7of7DNA7binding71,7HLH7protein
Nucleus
inhibitor7of7DNA7binding73,7HLH7protein
Nucleus
integrin7subunit7beta737binding7protein
Nucleus
JNK1/MAPK8$associated7membrane7protein
Cytoplasm
late7endosomal/lysosomal7adaptor,7MAPK7and7MTOR7activator71
Plasma7Membrane
MAD27mitotic7arrest7deficient$like717(yeast)
Nucleus
mediator7of7cell7motility71
Cytoplasm
metallothionein71X
Other
microsomal7glutathione7S$transferase71
Cytoplasm
mitochondrial7pyruvate7carrier72
Plasma7Membrane
mitochondrial7ribosomal7protein7L39
Cytoplasm
mitochondrial7ribosomal7protein7S14
Cytoplasm
mitochondrial7ribosomal7protein7S23
Cytoplasm
NA
NA
NA
NA
NA
NA
NADH:ubiquinone7oxidoreductase7complex7assembly7factor74
Cytoplasm
nitrilase7family7member72
Cytoplasm
nuclear7transport7factor72
Nucleus
oxidative7stress7responsive7serine7rich71
Other
PDZ7domain7containing711
Extracellular7Space
peroxiredoxin73
Cytoplasm
phosphatidylinositol7glycan7anchor7biosynthesis7class7U Cytoplasm
pleckstrin7homology7like7domain7family7A7member72
Cytoplasm
polymerase7(RNA)7II7subunit7G
Nucleus
polymerase7(RNA)7II7subunit7K
Nucleus
prefoldin7subunit71
Cytoplasm
protein7phosphatase767catalytic7subunit
Nucleus
proteolipid7protein727(colonic7epithelium$enriched)
Cytoplasm
replication7protein7A3
Nucleus
ribosomal7protein7L21
Cytoplasm
SAMM507sorting7and7assembly7machinery7component Cytoplasm
small7integral7membrane7protein77
Other
Tax17binding7protein73
Cytoplasm
thioredoxin7domain7containing712
Cytoplasm
thioredoxin7related7transmembrane7protein72
Other
transmembrane7protein7106C
Other
transmembrane7protein714A
Other
transmembrane7protein718
Nucleus
transmembrane7protein799
Other
Ts7translation7elongation7factor,7mitochondrial
Cytoplasm
ubiquitin7conjugating7enzyme7E27T
Nucleus
vacuolar7protein7sorting7257homolog
Cytoplasm
voltage7dependent7anion7channel73
Cytoplasm
WD7repeat7domain7837opposite7strand
Other
WDYHV7motif7containing71
Cytoplasm
zinc7finger7protein7706
Other

gene$class
enzyme
transporter
enzyme
enzyme
enzyme
other
other
kinase
enzyme
transporter
other
other
other
other
other
other
enzyme
translation7regulator
transcription7regulator
other
other
enzyme
enzyme
other
other
other
enzyme
other
transcription7regulator
transcription7regulator
other
other
other
other
other
other
enzyme
other
other
other
other
NA
NA
NA
other
enzyme
transporter
enzyme
other
enzyme
enzyme
other
enzyme
enzyme
transcription7regulator
phosphatase
transporter
other
other
other
other
transcription7regulator
enzyme
enzyme
other
other
other
other
translation7regulator
enzyme
other
ion7channel
other
other
other

ST1.2$>$Genes$Downregulated$in$SK>BR>3$Nuclei$Compared$to$Cells

Table 2 - Significant differentially expressed genes between SK-BR-3 whole cells and nuclei. ST1.1
lists all of the genes upregulated in nuclei compared to cells. ST1.2 lists all of the genes
downregulated in nuclei compared to cells. Columns listed include Gene Identifier (Gene ID), Foldchange, Entrez Gene Name, cellular localization and gene class.
We next investigated whether any biological differences could be detected between nuclear
and cellular transcriptomes. Our data suggest that the overall expression level and abundance of
genes are very similar (rs = 0.95) between nuclei and whole cells, consistent with the bulk experiments
(Figure 10a). Analysis of gene expression variance showed a bell-shaped curve, high correlation
(rho=0.451, Spearman Correlation) of gene expression values between all cells, and gene dropouts at
49

lower expression levels, justifying for the use of the zero-inflated negative binomial SCDE statistical
model (Figure
11). In totalTable
we detected
only 6.66%Enriched
(196/2942)
genes thatGene
were significantly
Supplementary
2 - Differentially
Oncogenic
Signatures Between SK-BR-3 Single Nuclei and Cells
Nuclei Enriched oncogenic genesets
GeneSet Identifier
CSR LATE UP.V1 UP
EIF4E UP
RB DN.V1 UP

Avg_diff
pval
adjPval
0.118060921
7.22E-38
1.14E-36
0.11607917
3.70E-56
2.33E-54
0.102414964
1.19E-40
2.49E-39

Whole Cell Enriched oncogenic genesets
GeneSet Identifier
Avg_diff
pval
adjPval
HINATA NFKB IMMU INF
-0.10104583
1.38E-13
5.23E-13
CSR EARLY UP.V1 DN
-0.11034172
2.12E-73
4.01E-71

Table 3 - The 5 out of 189 significant differentially enriched oncogenic gene signatures identified by
GSVA analysis between single nuclei and single cells. Columns listed include the Gene Signature
Identifier, Average difference of GSVA score between nuclei and whole cells (Avg_diff), p-value
(pval) and FDR adjusted p-value (adjPval).
differentially expressed using SCDE(158) (FDR adjusted p-values < 0.05 and |log2(fold change)| >=
1). Gene ontology and pathway analysis of these genes showed higher levels of LINC RNAs,
pseudogenes and nuclear-function genes in the nucleus compared to cells, while conversely the nuclei
showed low levels of mitochondrial and transmembrane genes, which were higher levels in the cells
(Figure 10b, Table 2). We also investigated whether the known RNA or protein localization in
cellular compartment showed any correlation with whether the RNA was expressed at high levels in
the nuclei or cells (Figure 10c). These data show that proteins and RNA that localize to the nucleus
are significantly elevated in nuclei, whereas proteins and RNA that localize to the cytoplasm are
higher in cells.
We further investigated whether any cancer genes or pathways were differentially expressed
in the nuclei and whole cells. We performed GSVA analysis(164) using 189 oncogenic gene set
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Figure 10 – Concordance in gene expression between single whole cells and nuclei. (a) Scatter plot
of average gene expression [log2(count+1)] of 485 single nuclei and 424 single cells, with 196
significantly differential genes labeled in purple and Spearmans’s correlation values indicated. (b)
Heatmap of selected differentially expressed genes that are LINC RNAs, pseudogenes, nuclearfunction genes, mitochondria or transmembrane. (c) Protein and RNA localization enrichment
analysis comparing genes overexpressed in the nucleus or cells. (d) Venn diagram and volcano plot of
GSVA scores for 189 oncogenic gene sets expressed in nuclei or cells. (e) Boxplots for 40 TCGA
breast cancer genes grouped by nuclei or cells, with a star indicating significant differential expression
in the CKS1B gene. (f) Breast cancer subtypes of single cells or nuclei predicted with the PAM50
gene signature. The frequency concordance was determined as non-significant by the Wilcoxon
matched-pairs signed rank test, where p-value > 0.4. (g) Clustered heatmap of single cell or nuclei
copy number profiles calculated from RNA data, compared to whole-genome-sequencing data
labeled as pop. Breast cancer genes are annotated on the WGS track.
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f
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signatures (MSiDB v5.2)(165), which showed that most signatures (97.35%) were highly concordant,
but that 5/189 gene sets were differentially expressed (Figure 10d, Table 3). The differentially
expressed gene signatures include 3 pathways that were upregulated in the nucleus (EIF4E
translation and nuclear export factors, RB cell cycle signaling and CSR serum starvation response)
and 2 pathways that were upregulated in the whole cells (NFKB inflammation and CSR serum
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starvation response). We also examined the expression levels of 40 breast cancer genes that are
frequently deregulated in TCGA(13) (Figure 10e). Only one gene, CDC28 protein kinase regulatory

a

c

b

d

Figure 11 - Calculation of data variation between gene expression levels in single whole cell and
single nuclei data from SK-BR-3. (a) Variance of all detectable genes in SK-BR-3 single cell data as a
function of mean expression levels. (b) Pair-wise correlation heatmap of all single nuclei and single
cells using 4414 top detected genes. (c) Scatter plot of two representative single cell gene expression
levels in log2(count+1) scale. (d) Scatter plot of single cell and single nuclei within group variations
of 196 significant genes detected between both groups by SCDE.
subunit 1B (CKS1B), was found to be significantly lower (2.4-fold) in the nuclei compared to the
cells. We also applied the PAM50 gene signature(193) to classify single cells into the 5 major clinical
breast cancer expression subtypes (Normal-like, Luminal A, Luminal B, Her2 or Basal-like). The
relative frequency shifted slightly in each group, however it was not significant by concordance test
(p-value > 0.4). These data showed that most of the single cells and nuclei were classified as Her2
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positive, consistent with the report that SK-BR-3 is a Her2 positive cell line by
immunohistochemistry(194). However, we also found that a subset of the single cells were classified
as luminal B (10.7, 23.6%), basal-like (1.8, 5.9%), normal-like (0.4, 1.4%) or luminal A (2.4, 3.3%) in
both the nuclei and cells (frequency concordance P > 0.4), suggesting that the population of cells
represented a composite mixture of molecular subtypes (Figure 10f).
We used the single cell gene expression data to calculate genomic copy number profiles at
~1 megabase resolution. A similar approach was previously applied to single cell RNAseq data from
glioblastoma patients(47). In our data we found that the copy number profiles of nuclei and wholecells were highly concordant (Pearson’s r =0.91) and identified several large-scale amplifications,
including 1q (MDM4), 7p, 8q (MYC), 17q (HER2), 19 and 20 (BCAS1) and deletions of 6q, 11p, 13,
17p (TP53), 18 (DCC) and Xp (Figure 10g). However, neither the single cell nor nuclei copy number
profiles could accurately resolve the smaller (<10mb) chromosome deletions and amplifications, and
we did not detect the MET amplification on chromosome 7q. The correlation between the single
cell or nuclei profiles and the whole-genome sequencing results was r =0.38 (Pearson Correlation).
Collectively these data suggest that transcriptome profiles of nuclei are highly representative of
whole-cells, and can be used to study many cancer genes and signaling pathways.

3.2.4 Phenotypic Diversity of Single Nuclei from a Breast Tumor
We applied nanogrid SNRS to study tumor subpopulations and transcriptional diversity in a triplenegative (ER-, PR- and HER2-) breast tumor that was cryopreserved for 2 years. Nuclear
suspensions were generated from the frozen tumor and 502 nuclei were sequenced using cDNA
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obtained with the nanogrid platform. In total we identified 1421 wells with single nuclei during the
imaging step and selected 502 wells with larger nuclei (>8 microns) to increase the tumor purity and
avoid sequencing normal stromal cells. The tumor purity was estimated by histopathology to be
41%. The data metrics resulted in an average of 975,097 reads, 14,886 UMI counts and 3,619 genes
per nucleus (Figure 12). We also used nanogrid SNRS to sequence 380 nuclei from a normal breast
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Figure 12 - Sequence data metrics calculated for single nuclei from the triple-negative breast tumor
analyzed by nanogrid SNRS, including: (a) Sequence read mapping rates to the human genome
reference assembly, (b) number of mapped reads per nucleus, (c) number of mapped reads in
millions, (d) number of unique molecular identifiers detected in single nuclei, (e) read tags mapped to
coding regions, (f) read tags mapped to intronic regions, (g) number of mapped reads per cell as a
function of gene coverage, (h) ribosomal RNA mapped reads, (i) mapped reads to the 3’ untranslated
region.
tissue sample. To distinguish between tumor and stromal cells, we calculated the genomic copy
number profile of each nucleus and clustered the data together with the normal breast tissue nuclei
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that showed diploid copy number profiles (Figure 13a). In our previous work, we have shown that
most tumor cells in breast cancer are aneuploid, while most normal cells have diploid profiles with
no evidence of somatic mutations(12, 17). Hierarchical clustering of the copy number data identified
5/502 cells with normal diploid copy number profiles representing stromal cells (Figure 13a, green
arrows) and 497 cells with aneuploid tumor profiles. The aneuploid tumor cells had amplifications in
chromosomes 1q (MDM4), 19q (AKT2) and deletions on chromosome 1p, 3, 4, 11p, 12q (MDM2),
17p (TP53), 19q, 22. These data suggest that the purity of the tumor cells increased from 41% to
99% using the automated imaging and selection of nanogrid wells with larger nuclei (Figure 13b).
We identified 497 tumor cells that had aneuploid copy number profiles and 5 normal breast tissue
cells with diploid copy number profiles from this analysis.
We first applied MAST(160, 161) to identify differentially expressed cancer genes (FDR
adjusted p-value<0.05 and [log2 (fold change)] ≥1 ) between single tumor cells (N=497), stromal cells
(N=5) and normal breast cells (N=240). This identified 30/229 known cancer genes (T200 targeted
platform) and 11/40 TCGA breast cancer genes that were differentially expressed relative to the
normal breast cells, including KRAS, GATA3, CCND1, CDH1, GNAS. Most of these genes were
expressed across all tumor cells; however, a few cancer genes, including AURKA and TOP2A were
restricted to a minor subpopulation.
To further understand phenotypic variability within the tumor cells, we focused on the 497
aneuploid tumor cells and performed PCA linear dimension reduction to identify the top variable
genes from the first 5 principal components (49.34% variance explained) for unsupervised clustering
using shared nearest neighbor (SNN) modularity optimization(171) (Figure 13c) and tSNE(174),
which was implemented with the SEURAT package(112)(Figure 5c-e). This analysis identified 3
subpopulations of tumor cells (clusters A, B, C). Subpopulation A consisted of 217 nuclei (52.2%)
and showed overexpression of 7 genes compared to other tumor subpopulations, which did not
include any known cancer genes. Subpopulation B consisted of 121 cells (29.1%) and showed
overexpression of 13 genes, including 7 cancer genes (HSPB1, ANXA1, SLPI, KRT8, KRT19, KLK7
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Figure 13 – Gene expression analyses of single breast tumor nuclei. ( a) Clustered heatmap of single
nuclei RNA copy number profiles isolated from tumor tissue or normal breast tissue. Green arrows
indicate 5 stromal cells from the tumor with diploid copy number profiles. Bar-plot shows increase in
tumor purity after image-selection of larger nuclei. (b) Enrichment of tumor cells using nanogrid
SNRS from 41% to 99%. (c) t-SNE projection of single nuclei in high-dimensional space with SNN
clustering of three subpopulations (A, B, C) indicated by color. (d) Clustered heatmap of single nuclei
RNA expression profiles using differentially expressed genes. Cancer genes are highlighted in red
and the three major clusters are indicated by color. (e) t-SNE plots of single cells showing gene
expression levels of individual genes. (f) GSVA scores for a subset of oncogenic phenotypes with
single nuclei sorted by each row independently with header bars indicating their identities of the
predicted subpopulations. (g) Clustered heatmap of cell cycle signature scores for single nuclei with
subpopulation indicated in the header. (h) Subtype signature classifications for single tumor nuclei
predicted by PAM50 for the 5 breast cancer subtypes (left) and for the 6 TNBC subtypes (right).
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and ABL2) and several Keratin genes (KRT8, KRT7, KRT19, KRT6B). Subpopulation C was the
rarest subpopulation (18.8%), consisting of 78 cells, but had the highest number of cancer genes
(N=13) that were overexpressed (MKI67, TOP2A, PRC1, CDK1, AURKA, CKS2, BIRC5, DEPDC1,
UBE2C, NEK2, BRCA2 and ECT2). Several genes that were differentially expressed in
subpopulation C are involved in DNA damage repair (BRCA2, RAD51AP1, HMGB2), apoptosis
(BIRC5, DEPDC1) and mitosis or cell cycle regulation, including high expression of Ki-67 (MKI67),
a marker of cell proliferation. To determine if the expression of the 13 cancer genes was truly
restricted to the minor C subpopulation, we plotted the individual gene expression levels of single
cells using Violin plots (Figure 13e). These data confirmed that most of the cancer genes were highly
elevated in subpopulation C and had low expression in the A and B subpopulations.
Due to the high level of Ki-67 in subpopulation C, we performed gene signature analyses for
the cell cycle stages (G1, S, M, G2) in all of the tumor nuclei (Figure 13g). These data showed that
many of the subpopulation C tumor cells were in the G2 or M-phase of the cell cycle, suggesting an
actively proliferating subpopulation, while many cells from subpopulation A and B were in the G1
phase or G0 (absence of scores). Our data suggest that while subpopulation C was the minor
subpopulation in the tumor mass, it also had the most malignant cancer phenotypes. The nuclei in
subpopulation C are likely to be in the G2 or M-phase, because the nuclear membrane does not
break down until prometaphase of mitosis and is re-formed during telophase. Therefore, there are
still some nuclei in prophase, prometaphase, telophase, and cytokinesis, that are mitotic. Interestingly,
the imaging data of nuclear signal and size showed that cells in the G2 or M-phase had significantly
larger sizes compared to those in other stages of the cell cycle (Figure 14), which is consistent with
previous observations that G2/M cells have larger nuclear diameters(195, 196). Our analysis of the
cell cycle data estimate that 18.75% of the cells were in the G2/M stage of the cell cycle, suggesting
that we did not bias strongly against other cell cycle stages by the selection of larger nuclei during the
nanowell imaging steps.
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Figure 14 - Boxplots of DAPI-staining intensities of G2/M single nuclei and G1/0/S single nuclei
as inferred by RNA-seq data was matched to automated imaging data from the nanogrid system,
showing larger nuclear sizes in the G2/M cells.
We further investigated the diversity of the classical breast cancer subtypes and oncogenic
gene signatures at single cell resolution. GSVA analysis identified variation in the gene signatures for
a number of cancer phenotypes, including stemness, proliferation, and angiogenesis (Figure 13f).
Consistent with our previous analysis, we found that subpopulation C was enriched for cell
proliferation, while subpopulation A showed low scores for proliferation. The GSVA data further
showed that subpopulation B had higher scores for hypoxia, invasiveness, migration, apoptosis and
glycolosis. Next, we used the PAM50 gene signature(193) to investigate the diversity of the 5 major
breast cancer subtypes and found that most cells were of the basal-like (156/416) subtype, which is
expected since this subtype is commonly associated with TNBC patients(193). However, we also
identified a significant fraction of single tumor nuclei that were Her2 positive (15.6%), luminal A
(3.4%), luminal B (26.4%) and normal like (17.1%), suggesting that the tumor was a mixture of
different subtypes (Figure 13h). Studies have also shown that TNBC patients can be further
classified into 6 additional subtypes based on gene expression signatures: mesenchymal (M),
mesenchymal stem-like (MSL), luminal androgen receptor (LAR), immunomodulatory (IM), basallike 1 (BL1) and basal-like 2 (BL2)(194). We applied the TNBC subtype signature to the basal-like
tumor nuclei and showed that most nuclei were classified as mesenchymal stem-like (90.1%) but that
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a few cells were immunomodulatory (4%) or belonged to the other TNBC subclasses (Figure 13h).
These data suggest that tumor nuclei demonstrate diverse cancer phenotypes and subtype
classifications within a single patient tumor.

3.3 Discussion
In this study we report a novel nanogrid SNRS technology that performs high-throughput single
nuclei imaging, selection and sequencing in an integrated platform. Nanogrid sequencing has several
technical advantages over existing high-throughput single cell RNA sequencing methods that use
microwells(108, 183, 184) or microdroplet encapsulation(110, 112). Our system enables automated
imaging of the 5184 wells that contain single cells or nuclei with fluorescent channels, followed by
selection of specific nanowells for nanodepositing of WTA reagents. Imaging and selection of single
cells is not technically feasible using microdroplet or microwell methods(110, 112). With nanogrid
imaging, we can reduce cell doublets and exclude dead cells by imaging. Another technical study
using the nanowell platform estimated the doublet error rate to be 2.4% by human-mouse mixing
experiments(153). Additionally, by staining nuclei with DAPI, our approach can select larger nuclei,
and thereby increase the purity of the tumor cells to 99%. This addresses a major issue in standard
RNAseq studies of tumor tissues wherein many normal stromal cells often affect gene signature
analyses. While a previous study has combined robotic micromanipulation and imaging(197) to
perform low-throughput single cell RNA sequencing (about 10 minutes per cell) and individual single
cell library construction, the nanogrid system completes imaging of all 5184 wells in only 10 minutes
and requires only a single sequencing library to be constructed for sequencing analysis. This greatly
reduces the cost to about $2.20 per cell, with the cost per 1800-cell library at $1.10 per cell and the
sequencing cost of $1.10 per cell for achieving 220K reads/cell on a HiSeq4000 system (Illumina).
Another study developed a nanowell system that uses barcoded mRNA capture beads to create a
portable, low-cost system called Seq-Well(198). While very cost effective and high-throughput, this
system did not allow selection of imaged nanowells, which is an advantage of our platform.
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We applied the nanogrid SNRS to study the transcriptional differences of cells and nuclei in
a breast cancer cell line, showing a high concordance in transcript abundance and expression levels.
These data challenge the long-standing paradigm that nuclear transcriptomes are not representative
of whole cells. However, our data are consistent with recent studies in neural cell types that have
reported a high concordance between the transcriptional profiles of nuclei and whole cells(109, 186188). We further applied nanogrid SNRS to study a frozen tumor sample from a TNBC patient that
was cryopreserved for about 2 years. On a parenthetical note, we do not expect that length of
freezing will have a major effect on the stability of nuclear RNA, although multiple freeze-thaw
cycles may lead to RNA degradation. In the TNBC tumor data, we identified a minor (19%)
subpopulation of tumor cells that were highly proliferative and overexpressed many cancer genes.
Our data also showed phenotypic heterogeneity in stemness, angiogenesis and proliferation, as well
as the co-existence of multiple breast cancer subtypes in single cells from an individual tumor. These
data are consistent with a recent single cell RNA sequencing study in glioblastoma that showed
variation in EMT and the co-existence of many clinical subtypes within an individual patient tumor.
The striking amount of pre-existing phenotypic variation may explain why TNBC patients evolve
rapid resistance to neoadjuvant chemotherapy(199-201).
Although the majority of nuclear and cytoplasmic genes were concordant, we did identify a
few differences in LincRNAs, pseudogenes, mitochondrial genes and nuclear-function genes. These
data are consistent with previous work showing that pseudogenes and LincRNAs are transcribed and
preferentially located in the nucleus over the cytoplasm(202, 203). Our data also determine that
mitochondrial genes are not expressed at high levels in the nucleus, which is consistent with the
localization of the mitochondria in the cytoplasm(204). We also found an increased abundance of
intronic sequences in the nucleus, which is expected based on our knowledge of alternative splicing
of pre-mRNA in the nucleus(191, 192). Importantly, our data indicate that these gene expression
differences did not have a major influence on the measurement of most cancer genes and signaling
pathways.
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In closing, the SNRS nanogrid system opens up new avenues of investigation into the
analysis of single nuclei transcriptomes from frozen tissue sections. In addition to imaging live and
dead cells and applying the parameter nuclear size, the nanogrid imaging approach is flexible and can
be applied broadly to identify cell types of interest based on fluorescent markers. We expect that the
SNRS nanogrid approach will benefit not only cancer research, as demonstrated in this study, but will
also benefit many diverse fields of biomedical research, where the analysis of single nuclei from
frozen tissue samples can provide new insights into human diseases.
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CHAPTER 4: CHEMORESISTANCE EVOLUTION IN TRIPLE-NEGATIVE BREAST
CANCER DELINEATED BY SINGLE CELL SEQUENCING

[Note: This chapter is based on a manuscript that has been accepted by Cell (Kim and Gao et al.
2018).]

4.1 Introduction
Triple-negative breast cancer (TNBC) is an aggressive subtype that constitutes 12-18% of breast
cancer patients (2). TNBC patients lack the estrogen receptor (ER), progesterone receptor (PR) and
HER2 receptor and therefore are not eligible for hormone or anti-Her2 therapy. Deep-sequencing
studies (11, 15, 205), multi-region sequencing analysis (28), and single cell sequencing studies (12, 16,
17) have shown that TNBC patients harbor high levels of somatic mutations, frequent mutations in
TP53 (83%) and complex aneuploid rearrangements (80%) that result in extensive intratumor
heterogeneity (ITH).
The standard of care for many TNBC patients is neoadjuvant chemotherapy (NAC), which
includes a combination of taxanes (mitotic inhibitors) and anthracyclines (DNA intercalators). While
NAC is effective in some TNBC patients, about 50% evolve resistance, leading to poor overall
survival (2, 7). The genomic and molecular basis of chemoresistance in TNBC patients remains
poorly understood, in part due to a lack of methods that can resolve ITH and detect genomic
information in rare subpopulations. A major gap in knowledge is whether chemoresistance arises
due to the selection and expansion of rare pre-existing subclones (adaptive resistance), or,
alternatively, through the induction of new mutations that confer a chemoresistant phenotype
(acquired resistance) (54). This question has been studied for decades in bacterial systems, since the
seminal fluctuation experiments by Luria & Delbruck (55) but remains poorly understood in most
human cancers.
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Genomic studies of therapy resistance have reported both acquired resistance (24, 63, 128,
206) and adaptive resistance (24, 64) to systemic chemotherapies. In acute myeloid leukemia, wholegenome sequencing before and after chemotherapy identified different modes of clonal evolution,
with some patients acquiring relapse-specific mutations, while others selecting minor clones (24). In
high-grade serous ovarian cancer, platinum-based chemotherapy was shown to induce new somatic
mutations consistent with acquired resistance (63), while resistance to cytotoxic chemotherapy in
bladder cancer was associated with the selection of pre-existing subpopulations (64). In
glioblastoma, treatment with temozolomide induced many new mutations in post-treatment tumor
samples consistent with an acquired model of therapy resistance (128, 206).
Previous work on chemoresistance in TNBC patients has mainly used in situ hybridization
methods (65) and bulk genomic profiling techniques (15, 205). With targeted cytogenetic markers,
one study showed that genetic diversity did not change in response to NAC but instead selected for
mesenchymal phenotypes (65). Another study in TNBC used next-generation sequencing (NGS) to
profile residual disease in post-treatment chemotherapy samples and identified a number of clinically
actionable mutations (15). In another report, authors identified JAK2 amplifications as a potential
therapeutic target to overcome resistant disease (66). However these studies were based on targeted
markers or bulk genomic tissue profiling and had limited ability to reconstruct clonal evolution
during chemotherapy.
Single cell DNA (12, 17) and RNA (42, 43, 108, 207) sequencing methods have emerged as
powerful tools for fully resolving ITH, reconstructing evolutionary lineages, and detecting rare
subpopulations (109, 208). The application of single cell DNA and RNA sequencing methods to
solid tumors has enabled phylogenetic reconstruction of tumor lineages (11, 12, 17), resolved rare
subpopulations (106, 197) and have provided insight into the phenotypes of stromal and tumor cells
in different cancer types (47, 127, 209). We reasoned that these technologies could overcome many
of the technical hurdles that have previously challenged genomic studies of chemoresistance in
TNBC patients.
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Figure 15 – Chemoresistance sample acquisition and study outline. (a) Timeline of chemotherapy
treatment schedule and sample acquisition. A pre-treatment core biopsy was obtained prior to NAC,
a mid-treatment core biopsy was attained after two cycles of NAC (docetaxel and epirubicin), and the
surgical sample was obtained after four additional cycles of NAC in combination with bevacizumab.
(b) For each longitudinal time-point sample, three analyses were performed, including bulk exome
sequencing, single-cell copy number profiling and 3’ single-nucleus RNA sequencing using a
nanogrid platform.
Due to the extensive ITH reported in TNBC patients, we hypothesized that genomic
aberrations associated with chemoresistance are pre-existing in the tumor mass and adaptively
selected in response to chemotherapy. In this study we analyzed longitudinal frozen treatment
samples collected from TNBC patients during NAC treatment. We identified two classes of clonal
dynamics in response to NAC, in which the mutations, CNAs and expression profiles were
eliminated from the tumor, or persisted after NAC. In the clonal persistence patients, our data
further showed that genomic mutations and copy number aberrations were adaptively selected in
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response to chemotherapy, followed by transcriptional reprogramming to evolve the resistant tumor
mass. Our approach of applying single cell DNA and single cell RNA sequencing allowed us to
identify these unique genomic and phenotypic methods of chemoresistance evolution, which we
would not have detected had we not used both methods.

4.2 Results
4.2.1 TNBC Patients Treated With Neoadjuvant Chemotherapy
We focused our study on 20 treatment-naive TNBC patients with local disease who were treated with
NAC (Table 4, Methods Section 2.1.1). All patients were classified as TNBC based on the absence
of estrogen receptor staining, progesterone receptor staining and HER2 copy number by FISH.
NAC treatment included an anthracycline (epirubicin) and a taxane (docetaxel) for 2 cycles, after
which patients received 4 cycles of the same chemotherapy in combination with an angiogenesis
inhibitor (bevacizumab) (Figure 15a). Frozen core biopsy samples were collected pre-treatment, after
2 cycles of therapy and during the surgical excision that occurred after 6 cycles of NAC. To mitigate

Patient
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
P13
P14
P15
P16
P17
P18
P19
P20

Identifier
KTN126
KTN129
KTN612
KTN304
KTN147
KTN206
KTN317
KTN210
KTN302
KTN102
KTN132
KTN134
KTN215
KTN152
KTN615
KTN316
KTN310
KTN115
KTN501
KTN155

Histological Type
IDC
IDC
Other
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
Not done
IDC
Other
IDC
IDC
IDC
IDC
IDC

Estrogen
Receptor
Baseline (IHC)
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%

Progesterone
Receptor
Baseline (IHC)
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%
<10%

Her2+
Baseline
IHC
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
2+
0 or 1+
2+
2+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+
0 or 1+

Her2+ FISH
Confirmation

KI67/MIB1
Proliferation
40
90
35
25
60
60
40
10
40
30
10
30
45
90
31
40
50
50

5-6 copies
FISH not amplified
FISH not amplified

FISH not amplified

N/A

Stage (ypTNM);
After Surgery

ypT1/Tis N0
ypT1 N0
ypTX/Tis N1
ypT0 N3
ypT0 N0
ypT1 N1
ypT0 N0
ypT1 N0
ypT1 N0
ypT3/Tis N3
ypT0/Tis N0
ypT0 N0
ypT0 N0
ypT2 N2
ypT1/Tis N0
ypT2/Tis N0
ypTX N1
ypT1 N0
ypT1 N0
50 ypT1 N1

Tumor Grade:
Baseline
Not done
3
Not done
3
2
Not done
3
2
2
3
3
3
Not done
3
Not done
Not done
3
2
3
3

Table 4 - Histopathological and clinical data on the 20 triple-negative breast cancer patients that
were analyzed in this study. Columns in this table include: 1) patient number, 2) patient identifier in
clinical trial, 3) histological type, where IDC = invasive ductal carcinoma, 4) estrogen receptor staining in
percentage of cells measured by immunohistochemistry, 5) progesterone receptor staining in percentage of
cells measured by immunohistochemistry, 6) HER2 receptor staining by immunohistochemistry, 7)
HER2 receptor amplification as measured by FISH, 8) tumor proliferation, as measured by Ki-67 and MIB1
expression, 9) TNM tumor stage after surgery, (yp = post-surgery; T = staging for main tumor; N =
staging for lymph nodes; M = staging for non-lymph node metastases) and 10) tumor grade.
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spatial variation from tumor sampling, two core biopsy samples from each time-point were collected,
and large tissue sections from the post-treatment surgical samples were used for genomic analyses.
Exome sequencing was performed on matchedlongitudinal samples from 20 TNBC patients, while
focused single cell DNA and RNA sequencing were performed on a subset of 8 patients (Figure
15b).

4.2.2 Clonal Extinction and Persistence of Mutations in Response to NAC
To investigate mutational evolution in bulk tissue samples, we performed exome sequencing (mean
depth 173×) on matched pre-treatment, mid-treatment and post-treatment samples from 20 TNBC
patients (Table 5, Chapter 2). Matched blood samples were sequenced in parallel (mean depth 126×)

Patient
P1
P1
P1
P2
P2
P2
P2
P3
P3
P3
P4
P4
P4
P4
P5
P5
P5
P6
P6
P6
P7
P7
P7
P8
P8
P8
P9
P9
P9
P9
P10
P10
P10
P10

Time Point Depth
Breadth
PRE
135
0.997
OP
179
0.994
BLOOD
96
0.997
PRE
166
0.985
MID
153
0.986
POST
169
0.986
BLOOD
161
0.986
PRE
187
0.998
POST
171
0.998
BLOOD
135
0.998
PRE
207
0.998
MID
117
0.998
POST
128
0.998
BLOOD
83
0.998
PRE
126
0.997
POST
104
0.997
BLOOD
128
0.998
PRE
133
0.997
POST
209
0.998
BLOOD
124
0.997
PRE
126
0.997
POST
104
0.997
BLOOD
128
0.998
PRE
123
0.998
POST
127
0.998
BLOOD
100
0.997
PRE
166
0.997
MID
159
0.997
POST
127
0.997
BLOOD
107
0.997
PRE
139
0.997
MID
111
0.996
POST
131
0.997
BLOOD
102
0.997

Patient
P11
P11
P11
P11
P12
P12
P12
P12
P13
P13
P13
P14
P14
P14
P14
P15
P15
P15
P16
P16
P16
P17
P17
P17
P18
P18
P18
P18
P19
P19
P19
P20
P20
P20

Time Point Depth
Breadth
PRE
189
0.986
MID
141
0.985
POST
144
0.985
BLOOD
172
0.986
PRE
172
0.986
MID
173
0.986
POST
153
0.986
BLOOD
111
0.985
PRE
145
0.997
POST
143
0.997
BLOOD
89
0.997
PRE
165
0.986
MID
153
0.986
POST
172
0.986
BLOOD
119
0.985
PRE
135
0.997
MID
105
0.996
BLOOD
109
0.996
PRE
166
0.998
POST
149
0.997
BLOOD
186
0.998
PRE
198
0.998
MID
234
0.998
BLOOD
172
0.998
PRE
162
0.986
MID
164
0.986
POST
161
0.986
BLOOD
139
0.986
PRE
129
0.998
POST
192
0.998
BLOOD
95
0.997
PRE
114
0.997
POST
131
0.998
BLOOD
108
0.997

Table 5 - Sequencing depth and breadth for whole exome sequencing calculated for the patients
at each time point. Average sequencing depth was 173x for tumors and 126x for matched blood.
Average breadth was >99% across all samples. The columns in this table include: 1) patient
identifier, 2) time point, 3) sequencing depth, 4) sequencing breadth
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to distinguish somatic mutations. Our data identified TP53 mutations in 60% (12/20) of the TNBC
patients, consistent with frequencies reported in TCGA (13). On average, 49 nonsynonymous
mutations (range 4-118) were detected in each patient. Among the 20 patients, 10 showed no
detectable mutations after treatment (Figure 16a), while 10 showed residual mutations after treatment
Patient Chr
P1
chr14
chr17
P6
chr5
chr11
P7
chr17
P8
chr1
chr16
chr16
P9
chr16
P10
chr2
chr2
P11
chr1
P12
chr2
chrX
P14
chr1
chr1
chr3
chr3
chr17
chr17
P16
chr1
chr3
P17
chr2
chr5
chr5
chr12
P19
chr1
chr14
chr17
chr17
chr20

Start

End
102906811
41246040
57752903
65623457
76388613
227174333
53496560
56667697
72991713
43986106
84928250
27121265
202359292
92927966
7792556
89848231
37107313
47048793
7577084
7756358
11889293
128181899
179441815
14610348
132270172
118671507
197070598
90429508
7578222
10304270
42682947

102906822
41246044
57752903
65623476
76388613
227174333
53496575
56667707
72991715
43986106
84928251
27121265
202359317
92927986
7792556
89848261
37107315
47048793
7577084
7756358
11889301
128181899
179441815
14610359
132270214
118671507
197070599
90429508
7578223
10304271
42682959

Ref
GCTTTTGCTTGT
TTTAA
GCATCATAGAGGGCATAGCG
C
G
ATTTATCTGTGAGTAA
GTGTGCCCACG
CCA
C
AA
CAGGTTGTATTAGCAGGTCCTGCAGT
TTTCTAAGCGCTTGCACACGA
G
AATGAATAAGAAGGGGGATTTCTTGCTGCAG
CTC
A
T
GTGGTGTTT
G
T
GGAGCCTCTCAG
GGAATGACTAGAGTTTAATGAAGAAACAGCCTGGGGTTTTCCA
TC
A
TC
TT
AGAAAAGAGACCT

Var
T
AG
CA
GCC
CAAATAT
-

Gene
TECPR2
BRCA1
PLK2
CFL1
PGS1
ADCK3
RBL2
MT1M
ZFHX3
PLEKHH2
DNAH6
PIGV
ALS2CR11
NAP1L3
CAMTA1
GBP6
LRRFIP2
NBEAL2
TP53
KDM6B
CLCN6
DNAJB8
TTN
FAM105A
AFF4
TAOK3
ASPM
TDP1
TP53
MYH8
TOX2

GenBank
NM_001172631
NM_007297
NM_006622
NM_005507
NM_024419
NM_020247
NM_005611
NM_176870
NM_006885
NM_172069
NM_001370
NM_001202554
NM_001168221
NM_004538
NM_015215
NM_198460
NM_017724
NM_015175
NM_001126115
NM_001080424
NM_001256959
NM_153330
NM_003319
NM_019018
NM_014423
NM_016281
NM_018136
NM_001008744
NM_001126115
NM_002472
NM_001098796

Exon
exon11
exon9
exon8
exon2
exon2
exon15
exon11
exon3
exon2
exon27
exon49
exon3
exon15
exon1
exon12
exon8
exon9
exon47
exon4
exon21
exon12
exon3
exon152
exon8
exon3
exon9
exon18
exon2
exon2
exon26
exon5

Nucleotide
c.2617_2628del
c.1363_1367del
c.1024dupA
c.241_260del
c.200delC
c.1839delG
c.1553_1560del
c.129_139AG
c.2330_2332del
c.4009delC
c.7848_7849del
c.740_741insCA
c.1747_1772del
c.318_338del
c.2963delG
c.1161_1191del
c.722_724del
c.7287delA
c.458delA
c.4651_4652insGCC
c.1096_1104del
c.190delC
c.42052delA
c.996_1007del
c.543_585del
c.614_615insATATTTG
c.7782_7783del
c.50delA
c.230_231del
c.3260_3261del
c.534_546del

Amino Acid
p.873_876del
p.L455fs
p.R342fs
p.R81fs
p.S67fs
p.M613fs
p.D518fs

Type
PRE-TREATMENT VAF MID-TREATMENT VAF POST-TREATMENT VAF BLOOD VAF
nonframeshift deletion
0.13
0.00
0.00
frameshift deletion
0.23
0.00
0.00
frameshift insertion
0.40
0.00
0.00
frameshift deletion
0.15
0.00
0.00
frameshift deletion
0.67
0.09
0.00
0.00
frameshift deletion
0.33
0.00
0.00
frameshift deletion
0.23
0.00
0.00
nonframeshift substitution
0.41
0.00
0.00
p.777_778del
nonframeshift deletion
0.10
0.03
0.00
0.00
p.R1337fs
frameshift deletion
0.24
0.18
0.00
0.00
p.S2616fs
frameshift deletion
0.27
0.17
0.04
0.00
p.T247fs
frameshift insertion
0.23
0.09
0.01
0.00
p.T583fs
frameshift deletion
0.33
0.00
0.02
0.00
p.106_113del
nonframeshift deletion
0.17
0.00
0.00
0.00
p.R988fs
frameshift deletion
0.31
0.09
0.31
0.00
p.T387fs
frameshift deletion
0.05
0.13
0.04
0.00
p.241_242del
nonframeshift deletion
0.21
0.12
0.18
0.00
p.I2429fs
frameshift deletion
0.21
0.23
0.11
0.00
p.E153fs
frameshift deletion
0.52
0.43
0.35
0.00
p.R1551delinsRR
nonframeshift insertion
0.27
0.16
0.15
0.00
p.366_368de
nonframeshift deletion
0.21
0.00
0.00
p.L64fs
frameshift deletion
0.19
0.00
0.00
p.S14018fs
frameshift deletion
0.31
0.11
0.00
p.332_336del
nonframeshift deletion
0.01
0.17
0.00
p.P181fs
frameshift deletion
0.17
0.00
0.00
p.W205_S206delinsX stopgain
0.01
0.18
0.00
p.Q2594fs
frameshift deletion
0.14
0.00
0.00
p.E17fs
frameshift deletion
0.00
0.15
0.00
p.R77fs
frameshift deletion
0.11
0.00
0.00
p.E1087fs
frameshift deletion
0.10
0.00
0.00
p.G178fs
frameshift deletion
0.10
0.00
0.00

Table 6 - Indels detected after local realignment with Mutect2, corresponding with somatic
mutational classifications of clonal persistence and extinction. The GBP6 indel in P6 has a raw posttreatment VAF of 0.04 but only <6 indel reads, which would be filtered out according to somatic
mutation filtration criteria. The columns in this table include: 1) patient identifier, 2) chromosome
number, 3) chromosome start position, 4) chromosome end position, 5) reference, 6) insertion or
deletion, 7) gene, 8) exon, 9) nucleotide, 10) amino acid, 11) indel type, 12) pre-treatment VAF, 13)
mid-treatment VAF, 14) post-treatment VAF, 15) blood germline VAF.
(Figure 16b). Notably, we did not observe an increase in mutation burden in response to NAC in
any of the TNBC patients.
We compared variant allele frequencies (VAFs) of somatic mutations before and after
therapy (Figure 2C-D) and applied PyClone2 (100) followed by CITUP clustering analysis (143) to
estimate clonal subpopulations from raw VAFs after normalization with copy numbers estimated by
exomeCNV (210) and tumor purity estimated by ThetA (210) from exome copy number (Figure 16cd). This analysis detected 2-4 major subclones in each TNBC patient and two distinct responses to
NAC: 1) clonal extinction, wherein clones were completely eliminated (Figure 16c), or 2) clonal persistence,
wherein clonal frequencies shifted but remained in the post-treatment samples (Figure 16d). Indel
frequencies corresponded with the categorization of clonal extinction and clonal persistence (Table
6), as did ThetA-derived tumor purity, which also correlated with histopathological cellularity
estimations (Table 7).
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Patient
P1
P2

P3

P4

P5
P6
P7

P8
P9

P10

P11

P12

P13
P14

P15
P16
P17
P18

P19
P20

Time Point ThetA Purity Histopathological Cellularity Classification
PRE
0.18
0
Extinction
POST
0.11
0
PRE
0.18
0.2
Extinction
MID
0.18
0.15
POST
0.04
0.15
PRE
0.33
0.5
Extinction
MID
0.25
0
POST
0.12
0
PRE
0.46
NA
Extinction
MID
0.15
NA
POST
0.09
NA
PRE
0.52
0.38
Extinction
POST
0.15
0
PRE
0.4
0.6
Extinction
POST
0.05
0
PRE
0.46
0.65
Extinction
MID
0.13
0.15
POST
0.04
0
PRE
0.32
0.9
Extinction
POST
0.03
0.2
PRE
0.55
NA
Extinction
MID
0.09
NA
POST
0.06
NA
PRE
0.51
NA
Persistence
MID
0.36
NA
POST
0.12
NA
PRE
0.12
0.78
Persistence
MID
0.1
0.55
POST
0.05
0
PRE
0.34
0.75
Persistence
MID
0.03
0.43
POST
0.12
0.1
PRE
0.2
0.4
Extinction
POST
0.06
NA
PRE
0.39
0.4
Persistence
MID
0.37
0.69
POST
0.37
0.75
PRE
0.12
0.4
Persistence
MID
0.19
0.6
PRE
0.19
0.6
Persistence
POST
0.06
0
PRE
0.33
NA
Persistence
MID
0.25
NA
PRE
0.16
NA
Persistence
MID
0.07
NA
POST
0.05
NA
PRE
0.19
NA
Persistence
POST
0.09
NA
PRE
0.32
0.75
Persistence
POST
0.18
0.63

NA = not available

Table 7 - Tumor purity determined by ThetA and by histopathological cellularity at different time
points. There was a high association between both ThetA and histopathological cellularity in
classifying patients into the clonal persistence or resistance groups. The columns in this table
include: 1) patient identifier, 2) time point, 3) ThetA purity, 4) averaged histopathological cellularity,
5) classification.
In the clonal persistence patients, most mutations were detected both pre-treatment and
post-treatment but had decreased frequencies in response to NAC (Figure 16d). However, we also
identified a number of new mutations (N=34) that emerged in response to NAC (Table 8). For
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example, in P17, we detected 13 new nonsynonymous mutations that emerged after NAC at the midtreatment time point, including nonsynonymous mutations in the apoptosis inhibitor, BIRC7, the
actin binding protein, PARVG, and the solute carrier, SLC6A9, which had significant proposed
Figure 16 - Bulk exome sequencing of matched longitudinal samples from 20 TNBC patients. (a)
Number of nonsynonymous somatic mutations in patients with no residual mutations after NAC. (b)
Number of nonsynonyous somatic mutations in patients with residual mutations after NAC. (c) Line
plots of raw variant allele mutation frequencies in left panels and inferred clonal subpopulations in
clonal extinction patients in the right panels. (d) Line plots of raw mutation frequencies in left panels
and inferred clonal subpopulations in right panels of clonal persistence patients. Mutations that were
specific to the post-treatment samples are highlighted in purple and labeled. (e) Targeted deep
amplicon sequencing to validate of pre-existing resistance-associated mutations in four clonal
persistence patients. Stars indicate that the mutations were statistically significant (mutated, p<0.05)
in the pre-treatment tumor samples by DeepSNV analysis. (f) A single patient (P19) in whom the
resistance-associated mutations in the post-treatment tumor sample were not statistically significant
(not mutated) in the pre-treatment tumor (ns, p>0.05) compared to the matched normal sample.

a

≈
ç

b
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functional impact based on SIFT (<0.05) (70) and POLYPHEN (P>0.85) scores (211). Similarly, in
patient P19, we identified 7 new mutations in the post-treatment sample, including a significant
nonsynonymous mutation in the solute carrier SLC5A8. While none of the resistance-associated
mutations recurred across multiple patients, they did share common biological functions, including
cell proliferation, apoptosis, solute transport, and cytoskeleton regulation (Table 8).
We next asked whether the new mutations detected post-treatment were spontaneously
induced due to acquired resistance, or alternatively, existed at very low frequencies pre-treatment, but
were not detected due to the limited sensitivity of exome sequencing (mean 173×). To address this
question, we selected a subset of post-treatment mutations (N=21) and performed targeted deepamplicon sequencing (789,000× mean depth) of the pre-treatment bulk tumor DNA (Table S9,
Chapter 2). We applied DeepSNV (144) to detect rare mutation frequencies that were statistically
significant compared to matched blood (sensitivity of 1e4). The amplicon data showed that in 4/5
patients, the suspected de novo mutations did in fact occur at low frequencies in the pre-treatment
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tumor (range 0.1-2%), consistent with adaptive resistance (Figure 16e). However, in one patient
(P19), the de novo mutations were not statistically significant over the normal sample (Figure 16f).
The mutations in this patients may have arisen de novo after the tumor cells were challenged with
chemotherapy, or alternatively may have not been sampled due to insufficient sequencing depth, or
sampling from different spatial regions.

Patient
P10
P10
P10
P11
P14
P14
P14
P14
P15
P15
P15
P15
P15
P17
P17
P17
P17
P17
P17
P17
P17
P17
P17
P17
P17
P17
P18
P19
P19
P19
P19
P19
P19
P19

Gene
PREPL
KHDRBS2
ZNF182
SHANK2
SLCO1B3
DCHS2
EIF2S2
C10orf120
SPEF2
ENAM
OTOL1
C16orf71
MYH9
KCNA10
BRINP2
SRRM3
C8orf76
OR5AS1
FLG
CACNA1E
LARP1
UTP14A
BIRC7
PARVG
SLC6A9
ELMO1
RBM23
SLC5A8
ACSL4
RHAG
ATG2B
TFPI
BLNK
AP2A2

Chr
chr2
chr6
chrX
chr11
chr12
chr4
chr20
chr10
chr5
chr4
chr3
chr16
chr22
chr1
chr1
chr7
chr8
chr11
chr1
chr1
0
chrX
chr20
chr22
chrX
chr7
chr14
chr12
chrX
chr6
chr14
chr2
chr10
chr11

Pos
44571019
62995789
47837151
70331655
21068984
155219314
32677631
124457906
35763706
71508463
161221587
4787886
36691666
111060626
177226485
75894114
124250127
55798011
152280610
181687234
154173703
129053189
61870793
44583712
135106536
37253033
23371268
101555836
108906629
49586961
96773253
188331710
97976416
993298

Ref
T
A
T
A
G
G
C
C
A
C
G
A
G
G
C
A
C
G
C
G
G
C
C
C
A
G
A
A
C
A
C
G
A
C

Var
C
G
C
G
T
A
T
T
T
A
A
G
C
A
G
G
T
T
T
T
A
T
T
G
C
T
G
G
G
T
T
T
G
G

Mutation Type
nonsynonymous
nonsynonymous
nonsynonymous
synonymous
nonsynonymous
nonsynonymous
nonsynonymous
synonymous
nonsynonymous
synonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
synonymous
synonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
synonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous
synonymous
synonymous

Validation
Yes
No
Yes
No
No
Yes
No
No
Yes
No
No
No
Yes
Yes
Yes
Yes
No
Yes
No
No
No
No
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
No
No
No

PRE
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.07
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

MID
0.14
0.12
0.21
0.00
0.00
0.00
0.00
0.00
0.13
0.092
0.10
0.109
0.14
0.12
0.16
0.11
0.13
0.12
0.119
0.09
0.18
0.22
0.25
0.13
0.132
0.228
0.00
-

POST
0.00
0.00
0.00
0.11
0.12
0.12
0.10
0.10
0.17
0.11
0.10
0.09
0.10
0.10
0.10
0.13

POLY
0.954
0.087
0.02
NA
0.001
0.002
0.996
NA
0.006
NA
0
0.985
0.808
0
0.999
0.993
0.983
0
0.99
0.962
NA
NA
0.998
0.979
0.956
0
NA
1
1
1
0.977
0.28
NA
NA

SIFT
0.68
0.2
0.31
NA
0.62
0.33
0.03
NA
0.88
NA
0.59
0.06
0
0.33
0
0.46
0.21
0.02
0.68
0
NA
NA
0.1
0.01
0
1
NA
0.01
0
0
0.31
0.95
NA
NA

Exon
exon5
exon1
exon6
exon10
exon16
exon18
exon9
exon3
exon26
exon9
exon4
exon3
exon26
exon1
exon4
exon9
exon3
exon1
exon3
exon12
exon7
exon6
exon6
exon5
exon12
exon12
exon11
exon13
exon14
exon2
exon30
exon8
exon7
exon12

Nucleotide
c.A481G
c.T65C
c.A278G
c.T2979C
c.G1912T
c.C4787T
c.G907A
c.G351A
c.A3703T
c.C1320A
c.G1291A
c.A215G
c.C3370G
c.C784T
c.C634G
c.A706G
c.G268A
c.G117T
c.G6752A
c.G1569T
c.G882A:p
c.C420T
c.C733T
c.C201G
c.A1414C
c.C861A
c.T1119C
c.T1546C
c.G1516C
c.T272A
c.G4304A:p
c.C868A
c.T600C
c.C1470G

Amino Acid
p.I161V
p.V22A
p.D93G
p.A993A
p.V638F
p.S1596L
p.E303K
p.P117P
p.M1235L
p.P440P
p.V431I
p.D72G
p.R1124G
p.L262F
p.L212V
p.K236E
p.A90T
p.M39I
p.G2251E
p.M523I
V294V
p.L140L
p.R245W
p.S67R
p.T472P
p.N287K
p.A373A
p.W516R
p.G506R
p.L91H
G1435D
p.Q290K
p.P200P
p.P490P

GenBank
NM_001171603
NM_152688
NM_001007088
NM_133266
NM_019844
NM_017639
NM_003908
NM_001010912
NM_024867
NM_031889
NM_001080440
NM_139170
NM_002473
NM_005549
NM_021165
NM_001291831
NM_032847
NM_001001921
NM_002016
NM_000721
NM_015315
NM_001166221
NM_139317
NM_001137605
NM_006359
NM_014800
NM_018107
NM_145913
NM_022977
NM_000324
NM_018036
NM_006287
NM_001258440
NM_001242837

Gene Function
serine-type endopeptidase activity
RNA-binding, alternative splicing
nucleic acid binding
postsynaptic activity
ion channel activity
cell adhesion
RNA-binding
ubiquitin ligase activity
protein dimerization
mineralization of enamel
glycoprotein secretion
NA
poly(A) RNA binding
ion channel activity
cell cycle
NA
G-protein coupled receptor activity
olfactory
keratin intermediate filament aggregation
voltage gated Ca2+ channel activity
RNA cap binding
large ribonucleoprotein complex
enzyme binding
actin binding
neurotransmitter:sodium symporter activity
binding
RNA-binding
transporter activity
long-chain fatty acid-CoA ligase activity
Rh transport
autophagy
blood coagulation, hemostasis
B cell development
binding / lipid binding

"-" = no sample

Table 8 - Table listing annotations in patients in whom new mutations were detected in the posttreatment tissue samples that were not detected in the pre-treatment tumor samples or were detected
at 2% ≤VAF. Three mutations in the genes AMPH, SPEF2, and MYH9, were at 0-2% VAF at
initial exome sequencing, but increased to 3-7% VAF after addition exome sequencing. Columns in
this table include: 1) patient identifier, 2) gene name, 3) chromosome number, 4) chromosome
position, 5) reference base, 6) variant base, 7) synonymous or nonsynonymous mutation type, 6)
status of whether the mutations was used for amplicon deep-sequencing, 7) pre-treatment mutation
frequency, 8) mid-treatment mutation frequency, 9) post-treatment mutation frequency, 10)
Polyphen prediction score for damaging impact, 11) SIFT prediction score for damaging impact, 12)
exon number, 13) nucleotide site of mutation in the gene, 14) amino acid substitution within the
protein, 14) genbank gene identifier, 15) extended gene function.

4.2.3 Copy Number Evolution and Clonal Extinction in Response to NAC
To investigate copy number evolution in response to NAC, we performed single-nucleus sequencing
(SNS) (12, 16) on 900 single cells from matched longitudinal samples of 8 TNBC patients (Methods
Section 2.1.1). We selected 4 clonal extinction patients (P1, P2, P6, P9) and 4 clonal persistence
patients (P10, P11, P14, P15) from the exome data. Single nuclei were isolated from aneuploid-gated
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distributions with FACS and used for sparse (~0.1×) whole-genome sequencing. The resulting data
were used to quantify genomic copy number at ~220kb resolution (Methods Section 2.5). FACS
analysis of DAPI-stained

a

b

Figure 17 – FACS profiles of a subset of patients before and after therapy. (a) FACS profiles of
DAPI-stained nuclei of 4 clonal persistence patients with identifiable aneuploid tumor peaks before
and after treatment. (b) FACS profiles of DAPI-stained nuclei from the 4 clonal extinction patients
with aneuploid tumor peaks that were less prominent or absent after NAC treatment.
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nuclei showed that the 4 clonal persistence patients had aneuploid distributions in both the pretreatment and post-treatment sample, while the 4 clonal extinction patients had low or undetectable
aneuploid distributions post-treatment (Figure 17).
To delineate the clonal substructure of the 4 clonal extinction patients, we obtained the
common breakpoints across all the cells in the population (212) and performed optimal clustering
(213) and t-SNE projection (214) using the short event matrix to avoid clustering artifacts that were
Figure 18 – Copy number evolution in clonal extinction patients. (a) t-SNE plots of single cell copy
number profiles from the pre-treatment and mid-treatment or post-treatment samples of four clonal
extinction patients with normal cells (N) and tumor subpopulations (A, B, or C) labeled. (b-e)
Clustered heatmaps of single cell integer copy number profiles and consensus integer copy number
profiles of clonal subpopulations. Consensus line profiles show annotated cancer genes and
subpopulation-specific differences indicated with grey bars. Lower panels showed analyses of clonal
dynamics calculated from optimal clustering results and maximal parsimony tree structures, and
plotted in TimeScape with cancer gene and clonal frequencies annotated.
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often introduced by parallel associations of uneven segment sizes (Methods Section 2.5). This
analysis identified 2-3 clusters of aneuploid tumor cells and one cluster of normal diploid cells in each
patient (Figure 18a). The aneuploid clusters were found exclusively in the pre-treatment tissues,
while the diploid clusters were mainly associated with the post-treatment tumor. However, a few
diploid stromal cells from the pre-treatment tumors also clustered with the post-treatment diploid
cells. Next, we computed consensus integer copy number profiles for each subclone, inferred clonal
lineages (Figure 19a) using the maximal parsimony tree method (Methods Section 2.6) and plotted
the clonal frequencies with Timescape (215). These data identified two major clones in three patients
(P2, P6, P9) and three major clones in the fourth patient (P1) in the pre-treatment tumors (Figure 18,
Figure 19a). Consensus profiles indicated that these multiclonal tumors shared common
evolutionary ancestors, as evidenced by shared CNAs, including early events in MET, MYC, and
PTEN in P6 (Figure 18b), MDM4, EGFR, and PTEN in P2 (Figure 18c), MYC and PTEN in P9
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(Figure 18d) and MYC, MET, TP53, CDKN2A and ALK in P1 (Figure 18e). These tumors also had
CNAs that emerged in the later stages of tumor evolution after diverging from a common ancestor.
However, irrespective of the number of clonal subpopulations, NAC led to the extinction of tumor
cells in these patients, with only diploid copy number profiles remaining after treatment.

a

b

Figure 19 - Maximum parsimony trees calculated from the consensus copy number event matrices
for 4 extinction patients (A) and 4 persistent patients (B) with each subpopulation highlighted in a
different color. The mutations labeled in the MP tree trunk were detected by piling up single cell
copy number sequencing reads at known mutation sites detected by bulk exome sequencing.

4.2.4 Adaptive Copy Number Evolution in Response to NAC
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To delineate copy number evolution in the 4 clonal persistence patients (P10, P11, P14, P15) we
detected 2-5 clusters of aneuploid tumor cell copy number profiles (Figure 20a) and constructed
maximum parsimony trees from the consensus clonal event matrix (Figure 19b). Strikingly, we found
that in all 4 patients, a minority of pre-treatment tumor cells (indicated with arrows) clustered with
the post-treatment tumor cells, suggesting that they shared a resistant genotype. To identify specific
Figure 20 – Copy number evolution in clonal persistence patients. (a) t-SNE plots of single cell
copy number profiles from the pre-treatment and mid-treatment or post-treatment samples of four
clonal persistence patients with tumor subpopulations (A,B,C,D,E) labeled. Arrows indicate preexisting single cells from the pre-treatment samples that share the post-treatment chemoresistant
copy number profiles. (b-e) Clustered heatmaps of single cell integer copy number profiles and
consensus profiles of clonal subpopulations. Consensus line profiles show annotated common
cancer genes and subpopulation-specific differences indicated with grey bars. Lower panels showed
analyses of clonal dynamics calculated from optimal clustering results and maximal parsimony tree
structures, and plotted in TimeScape with cancer gene and clonal frequencies annotated. Stars
indicate the chemoresistant clones that were selected and expanded in response to NAC.
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CNAs in the resistance-associated clones, we computed consensus copy number profiles from single
cells (Figure 20b-e). While most CNAs were shared between subclones, we identified specific CNAs
that occurred exclusively in the chemoresistant clones. In P14, resistance-associated clone A
displayed two focal deletions on chr 3p, including a 5.26mb hemizygous deletion of 3p26 (IL5RA)
and a 14.3mb hemizygous deletion of 3p24-22 (RARB). This clone expanded after NAC from 7.7%
to 71.8% post-treatment (Figure 20b). In P10, two resistance-associated clones emerged after NAC,
including clone C that expanded from 5.7% to 41.4%, and clone E that emerged mid-treatment at
2.6% and expanded to 37.8% (Figure 20c). The resistance-associated clone C had a 22.85mb
hemizygous deletion on chr 4p15 (PCDH7, DTHD1), a hemizygous deletion of a 5.75mb region on
chr11q21-22 (MAML2) and chr13q (RB1, BRCA2, FOXO1). In contrast, resistant clone E had a
23mb amplification of chr 19p (JAK3, BRD4) and a 20mb deletion on chromosome 20 (PAK7).
Expansion of the two minor clones with different genotypes suggests convergent evolution towards
a resistant phenotype. CNAs specific to the resistant subclones were also identified in P11 and P15
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by comparing consensus profiles (Figure 20d-e). However, our data did not reveal any recurrent
CNAs in the resistant clones among the 4 TNBC patients. Collectively, these results identified
chemoresistance-associated CNAs that were pre-existing in the tumor mass and selected in response
to NAC, supporting an adaptive resistance model in the clonal persistence patients.
For an integration of single cell copy number with bulk mutation data, we used Samtools to
pile up sparse single cell copy number reads to determine the presence of variant alleles at SNV sites
that were detected by whole exome sequencing (Methods Section 2.3, Figure 19a-b). Due to the high
sparseness of the single cell copy number data, we interpolated our observations to obtain maximal
mutational information on known mutation sites. Any sites that had non-zero read counts of variant
alleles in at least 2 cells were treated as mutated sites. We also interpolated the presence of a certain
mutation in a single cell as the presence of the mutation in the whole subpopulation that the cell
belonged to. With this approach, we were able to track truncal mutations that were shared by all
subpopulations, but our data depth did not allow us to detect mutations that were unique to
subpopulations.

4.2.5 Transcriptional Programs of Tumor Cells in Clonal Extinction Patients
We investigated phenotypic evolution in response to NAC using a high-throughput nanogrid single
nucleus RNA sequencing (SNRS) method (207). SNRS performs automated imaging and selection
of up to 1,800 single nuclei in parallel for 3’ mRNA profiling. We profiled the transcriptomes of
3,370 single nuclei isolated from two matched longitudinal samples per patient from the 4 clonal
extinction patients (P1, P2, P6, P9). An average of ~500 nuclei were selected from each time point
for SNRS, which resulted in an average of 1.2 million reads and 4,107 genes detected per cell. To
distinguish normal stromal cells from aneuploid tumor cells, we calculated copy number profiles
from RNA read counts (47), using a set of 240 diploid normal breast cells from a different patient as
a baseline reference (207) (Methods Section 2.8). Clustered heatmaps identified a large number (9099%) of aneuploid tumor cells in the pre-treatment tumor but only diploid cells post-treatment,
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Figure 21 – Transcriptomic evolution of clonal extinction patients. (a) Heatmaps of single cell copy
number profiles calculated from single cell SNRS data from pre-treatment and mid-treatment or
post-treatment samples from 4 clonal extinction patients, clustered together with 240 normal breast
cells from a different patient. (b) t-SNE projections of single cell RNA profiles from pre-treatment
and mid-treatment or post-treatment samples from each clonal extinction patient. (c) Violin plots of
single cell RNA profiles for four cancer genes, TOP2A, RAN, DEK and CKS1B that were
upregulated in the pre-treatment tumor cells across multiple patients. *, FDRadj p-value < 0.05,
0.58=< |log2(foldchange)| <1; **, FDRadj p-value < 0.05, |log2(foldchange)| >=1; (d) Cancer
gene signature analyses and clustering of GSVA scores for the tumor and normal cells from all 4
clonal extinction patients. (e) t-SNE projection of all single cell data from the four clonal extinction
patients, separating the tumor and normal cells in high-dimensional space. (f) Expression of
fibroblast marker ACTA2 and epithelial marker EPCAM in the tumor and normal cells. (g) Normal
cell type classification and frequencies in the post-treatment tissue samples.

a

b

c

86

d

e
e

f

g

consistent with the single cell copy number analyses (Figure 21a). We predicted the intrinsic breast
cancer molecular subtypes (163) and found that all 4 TNBC patients were dominated by basal
subtype of cells, but also had a small number of tumor cells with other subtype signatures (Figure
22c). We identified differentially expressed genes between the pre-treatment tumor cells and posttreatment normal cells (including fibroblast cells, basal and luminal epithelial cells) using the MAST
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method, where we regressed out the batch effects caused by the single cell gene detection rates (160)
(FDR-adjusted p-value < 0.05, |log2-fold change| > =1) (Methods Section 2.8) and performed highdimensional analyses to determine if tumor cells were present post-treatment (Figure 21b). We also
performed a parallel differential gene expression analysis without regressing out the gene detection
rates in single cells, which revealed high concordance in detection of differentially expressed genes
(72 – 99% concordance) in single cells (Figure 22a-b). This analysis identified distinct clusters of pretreatment and post-treatment cells, and further showed that no tumor cells were identified posttreatment, suggesting that they were eliminated by NAC. However, a few diploid stromal cells (N=29) from the pre-treatment tumors clustered with the post-treatment normal cells in patients P2, P6
and P9.
Differentially expressed genes in the 4 patients were identified and used to performed 2dimensional clustering, which showed that a number of genes were upregulated in the tumor cells
(mean = 590 genes) relative to the normal cells in the post-treatment samples, including several
known cancer genes (NRAS, MYC, FGFR2, TP53) (Figure 23a). In comparison to the posttreatment normal cells, pre-treatment tumor cells displayed increased enrichment scores in the
proliferation and regulation of apoptosis gene sets (Figure 23b-c). While most cancer genes were
unique to the individual patients, CKS1B, TOP2A, DEK and RAN were upregulated in multiple
patients (Figure 21c, Figure 23a). Notably, TO2PA has previously been shown to be a marker of
sensitivity to anthracyclines in chemotherapy studies of breast cancer (216). To determine if cancer
phenotypes were shared across the TNBC patients, we performed GSVA analysis (164) and
clustering on a set of cancer-specific signatures, which showed that the actin pathway, CDC42RAC
pathway, proliferation (217), mTORC1 signaling, unfolded protein response, regulation of apoptosis,
cancer meta signature (218), oxidative phosphorylation, and MYC targets (219) were upregulated in
the sensitive tumor cells relative to the normal cells in the post-treatment samples (Figure 21d).
We combined all the tumor and normal cell RNA data from the 4 patients, and performed a
high-dimensional analysis of the gene signatures with t-SNE (Figure 21e). The data showed that

88

a

b

c

d

Figure 22 - Venn diagrams of differential gene detection using MAST with or without single cell
gene detection rate correction in 4 clonal extinction patients (a) and 4 clonal persistence patients (b).
Classification of single tumor cells into the breast cancer subtypes (luminal A, luminal B, her2, basal
or normal-like) based on PAM50 gene expression and ordered in pentagram graphs where each dot
represents a single cell. (c) Breast cancer subtypes of clonal extinction patients in pre-treatment
tumor cells. (d) Breast cancer subtypes of single tumor cells in clonal persistence patients before and
after chemotherapy.
normal cells and tumor cells formed two distinct clusters. Importantly, these data did not show any
clustering of single cells by patient or batch, suggesting that batch effects were minimized in our
datasets by using the normalized GSVA scores. Within the normal cell cluster from the posttreatment samples, we found high levels of the fibroblast marker, ACTA2, and within the tumor cell
cluster from the pre-treatment samples, we found high levels of the epithelial marker, EPCAM

89

(Figure 21f). We further classified all normal cells in the post-treatment samples by 8 major breast
cell types using cell-type specific markers, which showed that fibroblasts were the most abundant
(mean 59.4% ± 16.2% SD) normal cells present after NAC, followed by T-cells (mean 6.9%) and
other CD45+ immune cells (Figure 21g, Methods Section 2.8.8, Figure 23d).
Figure 23 – Tumor and normal cell analyses of clonal extinction patients. Clustered heatmaps of
significant differentially expressed genes between pre-treatment tumor cells and post-treatment
normal cells including fibroblasts and epithelial cells with cancer genes annotated (a). Boxplots of
single cell geneset enrichment scores in extinction patients for the proliferation gene set (b) and the
regulation of apoptosis gene set (c). Normal cell types were classified into 8 groups based on cell
type-specific markers in the post-treatment normal cells from the 4 clonal extinction patients (d).
Heatmaps indicate average expression of markers in single cells from each patient.
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4.2.6 Acquired Evolution of Transcriptional Programs in Chemoresistant Tumor Cells
To investigate phenotypic evolution in the clonal persistence patients (P10, P11, P14, P15), we
conducted SNRS on ~400 nuclei from each matched time point, resulting in an average of 1.2
million reads and 5,166 genes detected per cell. The treatment time points for P11 and P15 were
mid-treatment samples, while P10 and P14 included post-treatment samples. We calculated copy
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Figure 24 – Transcriptomic evolution of clonal persistence patients. (a) Heatmaps of single cell
copy number profiles calculated from single cell RNA data from pre-treatment and mid-treatment or
post-treatment samples from 4 clonal persistence patients. (b) t-SNE projections of single cell RNA
profiles from pre-treatment and mid-treatment or post-treatment samples from each clonal
persistence patient, with arrow indicating two cells from the pre-treatment samples that cluster with
the post-treatment expression profiles in patient P11. (c) Venn diagrams and clustered heatmaps of
significant differentially expressed genes between the pre-treatment tumor cells and post-treatment
tumor cells with cancer gene annotations. (d) Violin plots of single-cell GSVA scores for the pretreatment and post-treatment tumor cells from all 4 clonal persistence patients. (e) t-SNE projection
of all single cell data from the four clonal persistence patients, separating the pre-treatment and posttreatment cells in high-dimensional space irrespective of patient origin. First panel is colored by timepoint; fifth panel by patient, and other panels showed relative gene set enrichment scores for single
cells.
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number profiles from the single cell RNA read TPM data (Methods Section 2.8) and performed 1dimensional clustering (Figure 24a). In contrast to the clonal extinction patients, a large fraction of
aneuploid cells (85-99%) were detected in both the pre-treatment and post-treatment samples,
consistent with the single cell copy number data. The few normal diploid cells that were detected in
these samples were removed from subsequent expression analyses.
To determine whether any of the tumor cells with chemoresistant expression profiles existed
at low frequencies in the pre-treatment tumor, we performed high-dimensional analysis (Figure 24b,
Chapter 2). In three patients (P15, P14, P10), we did not detect any pre-existing transcriptional
profiles that clustered with the post-treatment tumor cells, despite profiling hundreds of cells. To
identify genes upregulated in the chemoresistant post-treatment tumor cells, we performed
differential expression analyses using MAST (FDR adj p-value < 0.05; |log2 fold change|>=1) and
identified a number of differentially expressed genes (N=59-275) in each patient (Figure 24c). A few
differentially expressed genes were known cancer genes (MYC, ERBB3, KIT and PIK3R1) but were
not recurrent among the patients (Figure 24c).
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Molecular subtyping prediction showed that these tumors were prevalent with basal subtypes
of cells except in one patient (P11) in which a number of tumor cells were classified as HER2+, as
well as luminal A and B (Figure 22d). Interestingly, P11 was HER2+ by IHC protein levels however
did not have any copy number amplifications by FISH (Table 4). These data show that the subtype
composition of single cells did not change drastically in response to NAC, suggesting that subtypeswitching did not occur (Figure 22d). Next, we used t-SNE to cluster all the single cell data from the
4 patients in high-dimensional space, which separated the pre-treatment and post-treatment tumor
cells into two distinct clusters with single cells from different patients intermixed within each major
cluster (Figure 24e). We labeled the chemoresistance gene signature scores of single cells in the highdimensional plots, which showed that they were highly enriched in the post-treatment samples,
consistent with the gene signature heatmap clustering results (Figure 24e).
To identify common phenotypes of the chemoresistant tumor cells, we performed single cell
gene signature analysis using GSVA for a set of cancer-related signatures and clustered the
normalized scores from all 4 patients (Methods Section 2.8.4, Figure 24d). This analysis showed that
gene signatures including degradation of ECM, AKT1 signaling via mTOR (220), CDH targets (221),
hypoxia (222), EMT and Angiogenesis were upregulated in the chemoresistant tumor cells after NAC
(Figure 24e). High expression of genes involved in AKT1 signaling via mTOR and hypoxia was
associated with statistically significant worse survival (Figure 25), and hypoxia in particular was
chemoresistance-associated because it did not affect survival in TNBC patients who did not receive
chemotherapy (Methods Section 2.8.9).
To investigate whether resistance genes were partially activated in pre-treatment cells, we
clustered pre-treatment single cells with post-treatment single cells in 4 persistent patients using a
CNA matrix calculated from SAVER-rescued (223) single cell RNA sequencing data to define a
group of non-resistant single cells that did not have resistant CNAs in pre-treatment tumors and a
group of resistant single cells that had resistant CNAs in post-treatment tumors. We compared the
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resistant single cells to non-resistant single cells using MAST and used the top variable genes (FDR
adj p-value < 0.05; |log2 fold change|>=1.58) to perform random forest selection and to classify all
single cells from each patient into the resistant or non-resistant group (Methods Section 2.9.2). In
three patients (P10, P11 and P14), we detected pre-treatment cells (3-33 cells) that expressed a
fraction of the resistant genes (Figure 26a-b), suggesting that although a pre-existing genotype may
prime cells, a second step of phenotype switching is required for resistance activation. In order to

Figure 25 - Survival analysis from the METABRIC dataset for breast cancer patients that received
chemotherapy, grouped by the enrichment scores of six selected gene sets that were enriched in posttreatment resistant cells.
integrate mutational subpopulations with single cell RNA data, we tracked mutations that were
present in the 3’-ends of transcripts. However, due to the sparseness of the single cell RNA
sequencing reads, we were only able to use this approach to confirm our classifications of persistence
and extinction patients (Figure 26c-d).
4.3 Discussion
In this study we investigated genomic and phenotypic evolution of TNBC patients in response to
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Figure 26 – Integration of genomic and phenotypic data. a) Prediction of resistance activation in
single cells in 4 persistence patients. Labels are colored by NAC time point. Single cells defined as
primed pre-treatment cells that had resistance activation scores above 17.2% are illustrated as blue
stars. (b) t-SNE projection of pre-treatment single cells (blue) and post-treatment single cells (red).
Primed pre-treatment single cells are highlighted with turquoise stars. Oncomap of somatic
mutations from whole exome sequencing that were also detected in single cells via reads from single
cell RNA sequencing. Detected variants noted in red, detected reference bases noted in white, and
low-coverage reads (<2 reads at the site) noted with a diagonal line. Patient classifications of clonal
persistence and extinction were maintained in the single cell RNA sequencing data, with clonal
persistence patients (c) demonstrating residual mutations by RNA sequencing and clonal extinction
patients (d) demonstrating elimination of mutations. (e) Adaptive evolution in response to
neoadjuvant chemotherapy (NAC) leads to the selection of minor clones with chemoresistant
genotypes and phenotypes. (f) Acquired evolution in response to NAC leads to induction of new
mutations and phenotypes in response to the therapeutic agent. (g) Adaptive genomic and acquired
phenotypic evolution occurs in two steps, wherein the genotypes are first selected and expanded in
response to NAC after which transcriptional reprogramming occurs leading to chemoresistant
phenotypes in primed cells.
treatment, including many fibroblasts and immunocytes. In contrast, in the clonal persistence
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patients, the post-treatment tumors harbored a large number of tumor cells with genotypes and
phenotypes that were altered in response to NAC. Using single cell DNA and RNA sequencing
methods we performed a higher resolution analysis of 8 patients, which showed that CNAs that
emerged in response to NAC were pre-existing and adaptively selected, while the expression profiles
were mostly acquired through transcriptional reprogramming. We speculate that the genotypes
selected by NAC are primed for transcriptional reprogramming and therefore provide an
evolutionary advantage over tumor cells that are sensitive to chemotherapy (Figure 26e).
Collectively, our data suggest that chemoresistance evolution is mediated by the adaptive selection of
genomic aberrations and transcriptional reprogramming to establish the resistant tumor mass.
Our study is particularly novel because it uses both single cell DNA and single cell RNA
sequencing to delineate the evolution of TNBC tumors in response to chemotherapy. Although our
previous work has investigated genomic evolution in TNBC at single-cell resolution (16, 17), and
other studies have applied single cell RNA sequencing to TNBC (19), the present study is significant
because it demonstrates how genomic and phenotypic evolution display two different methods of
chemoresistance across longitudinal samples. Without conducting both DNA and RNA single cell
sequencing, we would not have been able to identify the process of chemoresistance evolution in
TNBC wherein mutations and CNAs are adaptively selected and prime cells for acquired
transcriptional reprogramming.
Our data in TNBC patients contrast with previous genomic studies in other human cancers, in
which chemotherapy in glioblastoma and ovarian cancer show large increases in mutation frequencies
in the post-treatment sample (24, 63, 127). In our exome data, we observed decreases or no changes
in the mutation frequencies in the post-treatment samples in response to NAC. These data may
reflect the different chemotherapeutic agents that were used to treat the glioblastoma and ovarian
cancer patients, since cis-platinum and telozolomide have been shown to be highly mutagenic. In
contrast, neoadjuvant chemotherapy in this study included taxanes (paclitaxel), anthracyclines
(epirubicin) and angiogenesis inhibitors, which are not known to be highly mutagenic. Our results

98

are consistent with a previous study in TNBC, which reported no significant increase in somatic
mutations after treatment with chemotherapy (15).
While the mutations and CNAs that were selected in response to NAC constituted diverse
biological functions, the transcriptional programs indicated several common gene signatures and
pathways associated with chemoresistance across the 4 patients. Some gene networks relate directly
to the responses from the therapeutic agents, while others are likely to be associated with resistance
mechanisms. For example, the mesenchymal phenotypes we observed in post-treatment tumor cells
have been shown to desensitize tumors to cytotoxic agents (88). Studies using immunocytochemistry
have also showed that breast tumor cells in post-NAC samples harbor mesenchymal phenotypes
associated with resistance (65), consistent with our data. In the context of therapy, decreased anoikis
permits cancer cells to survive upon detachment from the ECM to gain metastatic potential (224),
while TNF signaling can alter the tumor microenvironment, inducing angiogenesis, EMT, and ECM
remodeling (225). These phenotypes may play an important role in conferring a chemoresistant
phenotype, but will require future functional studies using in vitro and in vivo models to understand
their mechanisms.
Our data has several important clinical implications. First, the pre-existence of chemoresistant
genotypes in the tumor mass indicates there may be diagnostic opportunities for detecting
chemoresistant clones in TNBC patients before NAC, to predict which patients are most likely to
benefit from chemotherapy. Second, the stratification of TNBC patients into clonal extinction and
clonal persistence groups may have prognostic implications for predicting patient outcome or
survival, however such studies will require larger cohorts of patients with longitudinal samples.
Third, our data on chemoresistant phenotypes raise the possibility of therapeutic strategies to
overcome chemoresistance, such as targeting EMT signaling (226) or TNF signaling (227) to
resensitize the tumor cells to chemotherapy and eliminate the tumor mass.
Notable limitations to our study include the total number of patients (N=8) that were analyzed
at single cell resolution. Future work will need in a larger cohort of TNBC patients to understand the
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generalizability of the chemoresistance-associated phenotypes and the evolutionary model that was
identified in this study. Although batch effects have been identified as a major confounding effect in
single cell RNA data (228), we mitigated these errors by processing all samples in parallel, using
identical reagents, and correcting for batch effects in our data post-processing steps. The global
analysis of the tumor cells in high-dimensional space, shows that single cells cluster by treatment time
point rather than by patient, suggesting that batch effects did not significantly affect our datasets
when using individually normalized single cell GSVA scores. Another potential source of error is in
spatial bias in the core biopsy samples, which we mitigated by using two independent ultrasoundguided core biopsy samples from each time point and by using large surgical specimens from the
post-treatment time points.
In closing, we expect that the approach reported here will provide new insights into
chemoresistance evolution in many human cancer types. In most human cancers chemotherapy
remains to be the first line of therapy and standard of care, in which the tumors often respond well
initially but frequently develop resistance within the first few years. Important future directions will
also include the analysis of metastatic tumors that are matched to primary tumor samples from the
same TNBC patients, to understand whether the chemoresistant clones in the primary seed
metastases and also confer resistance at distant organ sites. These studies will become more feasible
as single cell DNA sequencing technologies increase in throughput and decrease in cost (181), and
the ability to sequence both DNA and RNA in the same cell becomes more technically accessible
and high-throughput (126).
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
5.1 Conclusions
In my dissertation, I demonstrate the phenotypic heterogeneity of TNBC tumors by developing a
nanogrid-based single-nucleus sequencing method that can be applied to frozen tissue samples. I
also delineate the genomic and phenotypic evolution of 8 TNBC tumors in response to
chemotherapy with deep WES, single-cell copy number sequencing, and single-nucleus RNA
sequencing. In patients with clonal persistence of somatic mutations, genomic resistance is adaptive
through the expansion of pre-existing mutations and copy number aberrations. Conversely,
phenotypic resistance driven by reprogrammed transcriptomic programs that confer a chemoresistant
phenotype.
This study is particularly novel because it uses both single cell DNA and single cell RNA
sequencing to delineate the evolution of TNBC tumors in response to chemotherapy. Although
previous work has investigated genomic evolution in TNBC at single-cell resolution (16, 17), and
other studies have applied single cell RNA sequencing to TNBC (19, 229), the present study is
significant because it shows how genomic and phenotypic evolution display two different methods of
chemoresistance across longitudinal samples. Without conducting both DNA and RNA single cell
sequencing, I would not have been able to identify the process of chemoresistance evolution in
TNBC wherein mutations and CNAs are adaptively selected and prime cells for acquired
transcriptional reprogramming. These final conclusions of my dissertation are based on a NGS
approach with the primary objective of investigating chemoresistance in TNBC from an unbiased
genome-wide perspective. They inform us of the common evolutionary paths that exist in the
context of chemoresistance for TNBC patients and emphasize the importance of conducting both
DNA and RNA analyses in the same longitudinal samples.

5.2 Future Directions
5.2.1 Advances in Single-Cell Epigenetics and Whole Genome Sequencing
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Within the genomics-based scope of my thesis project, I can only theorize the mechanisms of
adaptive genomic resistance and acquired phenotypic resistance in TNBC. The first theory is
epigenetic modification of genotypes that are primed to produce chemoresistant phenotypes. Since
resistance-associated somatic mutations and CNAs pre-exist prior to treatment, perhaps they are
uniquely equipped to undergo reversible epigenetic changes that influence gene expression and
consequently alter cell phenotypes. Recent studies in high-throughput epigenetic SCS(49, 113) have
successfully identified differential methylation patterns that affect transcription, and there are many
single-cell epigenomic methods that can resolve the epigenetic states of individual cells(230). These
approaches can determine the regions of the genome that experience epigenetic changes during
chemoresistance evolution.
In light of the fact that the exome comprises only a small fraction of the entire genome, I
also posit that mutations in the noncoding genome affect the phenotypic plasticity of chemoresistant
cells.

Conceivably there are differences between the whole-genome mutational profiles of

chemoresistant cells versus non-chemoresistant cells, with chemoresistant cells potentially harboring
key adaptive resistance-associated mutations in noncoding genes that are absent in chemosensitive
cells. Although it is difficult to gauge the functional significance of noncoding mutations, they may
be just as important as coding mutations in their ability to experience epigenetic modifications and
alter phenotypes. Currently, the field of cancer genomics is limited by the high-cost and lowthroughput nature of single-cell WGS, but future technological advances can increase the feasibility
of examining the noncoding genome in chemoresistance evolution.

5.2.2 Associations Between Genotype and Phenotype
Although separate genomic and phenotypic analyses provide key details to chemoresistance, an
integration of genomic and phenotypic data is the most direct way of assessing both aspects of tumor
evolution. Future work should investigate modes of chemoresistance evolution in the same cells at
single-cell resolution. In Chapter 1, I reference advances in next-generation sequencing that allow
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genome and transcriptome sequencing from the same cell and note the low-throughput nature of
these new methods. Potential alternatives include calling mutations in full-length RNA
transcripts(43), sequencing DNA and RNA from the same cell(73), or extracting more specific CNA
data from RNA sequencing(231) in order to determine that cells with chemoresistant gene signatures
also harbor pre-existing resistance-associated somatic mutations or CNA profiles.
Phenotypes themselves quite possibly exist on a gradient that begins with the early stages of
carcinogenesis and eventually leads to chemoresistance. In Chapter 4, I identify several gene
signatures and transcriptional programs that are acquired after chemotherapy, but it is difficult to
ascertain whether individual signatures portend chemoresistance or whether an aggregation of
different signatures is required to achieve that phenotype. This is further complicated by the
possibility that a different single-cell RNA sequencing method would have been able to detect more
genes and therefore provide more comprehensive resistance-associated phenotypes. Furthermore,
without functional studies, I can only postulate from my NGS observations that the identified
signatures contributed extensively to chemoresistance. As a result, the phenotypic evolution data will
ostensibly benefit the most from functional validations as well as cross-validations with alternative
RNAseq methods. Individual genes, combinations of genes, or entire gene signatures identified in
silico can be experimentally overexpressed or knocked out to evaluate effects on chemoresistance in
vitro.

5.2.3 Single Cell Sequencing in the Tumor Microenvironment
Single cell sequencing enables an in-depth analysis of not only tumor cells but also cells present in the
surrounding microenvironment. In doing so, it allows us to study the non-tumor factors, such as
immunocytes and normal cells, which shape tumor evolution. By investigating the tumor
microenvironment, we can determine the underlying causes of intratumor heterogeneity in the
context of environmental alterations and explain why tumor clones and subclones persist despite the
body’s immune defenses. For example, paired single cell sequencing of stage I lung adenocarcinoma
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tumor cells, normal cells, and immunocytes reveals a relative increase in T cells and mononuclear
phagocytes in tumor tissue versus normal tissue(232). Likewise, in primary breast cancer of various
subtypes, single cell RNAseq indicates a preponderance of immunosuppressive T lymphocytes
(regulatory or exhausted phenotype) or M2 macrophages(19). Identification of aberrant
immunocytes in tumors can potentially elucidate methods to overcome resistance to immunotherapy
across different cancer types(233)

5.2.4 Clinical Potential and Precision Medicine
An ongoing theme throughout this thesis is the superior capacity of single cell sequencing to find and
to characterize cells that influence medically relevant phenotypes. With its high resolution, single cell
sequencing has the potential to identify rare populations that harbor robust clinical consequences,
such as drug resistance and metastasis. Conveniently, advances in single cell sequencing have
coincided with advances in targeted genome editing, and an integration of these modalities can
inform and amend precision medicine.
We start with a scenario where we characterize metastatic subclones by conducting singlecell comparisons between a primary tumor and its corresponding metastatic site. We then verify the
functional significance of the genes in the metastatic subclone through a CRISPR-Cas9 screen that
determines whether a particular gene of interest wields a driving influence on metastasis. Finally, we
pool together targeted knockouts of the screened genes for an in vitro or in vivo (xenograft)
experiment to observe whether knocking out drivers will affect metastatic rate. This last step can be
altered to include therapies that target validated sets of genes.
Here it is important to note that segments of our overall approach have been previously
published or at least have proven to be feasible. Single cell transcriptome analyses of head and neck
squamous cell carcinomas and their matched lymph node metastases have identified a partial EMT
signature that exists in the primary tumors as a precursor to the full EMT signature present in the
lymph nodes(234). Our own data in the context of chemoresistance display a similar pattern, where
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single cell sequencing reveals primed signatures in the pre-treatment biopsies (Chapter 4). Both
positive and negative CRISPR-Cas9 screens have also been used to distinguish genes that are
necessary for cancer cell survival or confer resistance to cancer therapies(235). Although there are no
existing studies that combine single cell sequencing with targeted genome editing, this integration is
certainly a realistic endeavor. From a clinical perspective, it allows us to: 1) pinpoint genes with
potential phenotypic importance at single-cell resolution, 2) test the functional significance of the
genes with high-precision genome editing, 3) evaluate the aggregate phenotypic benefits of pooled
genome editing, and 4) find therapies, therapeutic combinations, and therapeutic sequences for gene
sets with confirmed phenotypic significance (under the presumption that genome editing has not yet
been approved for clinical use).
The aforementioned process is not necessarily limited to cancer, and there are many
branches of medicine that could benefit from high-resolution sequencing and high-precision genome
editing. One option is the application to progressive chronic kidney disease (CKD), where the
transition to end-stage renal disease (ESRD) is multifaceted and involves stepwise deficits in different
renal structures. Multi-region single cell sequencing of the kidney at different CKD time points in
experimental models of renal failure can elucidate the genotypic, phenotypic, and anatomical
progression to ESRD. Furthermore, a detailed analysis at various stages of kidney injury can shed
light on potential protective mechanisms against further deterioration.

5.2.5 Importance of Single-Cell Sequencing
The results of this dissertation attest to the two-fold importance of single-cell sequencing in defining
rare cellular populations: 1) single-cell sequencing at the RNA level can preferentially isolate and
profile tumor cells after distinguishing them from normal cells with copy number profiles inferred
from RNAseq and 2) single-cell CNA and RNA sequencing can identify profiles that exist in minor
fractions of cells. We strongly believe that the pre-existing genotypic populations would not have
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been identified with bulk sequencing. Similarly, we posit that that bulk RNA sequencing would have
been confounded by stromal contamination and immunocyte infiltration.

5.3 Limitations and Looking to the Long-Term Future
(aka Pipe Dreams)

As geneticists in the era of tremendous technological advances, we often feel a premature urgency to
emphasize the practical and clinical benefits of next-generation sequencing and big data genomics.
Every presentation on cancer genomics touts the applicability of genomic sequencing methods to
human patients – from early tumor detection to precision medicine. However, bench-to-bedside
translations are not infrequently obstructed by various logistic problems inherent to the approach
and design of genomic studies. Firstly - to the exclusion of a pan-cancer paradigm – much of clinical
oncology is still stratified into organ systems and disease sites. Although TCGA has pursued a pancancer research initiative that analyzes common aberrations across different tumor types, this line of
thinking has not yet been integrated into the clinic. Perhaps we will benefit from a future generation
of oncologists who can evaluate the significance of genomic and phenotypic aberrations across
tumor types as well as within specific organs.
Secondly, NGS studies can be under-powered, restricted by the availability of patient
samples, resulting in scientific conclusions that are applicable to only a controlled subset of patients.
Indeed, larger sample sizes are needed to validate results and generalize them for functional
purposes. When prospective studies are not feasible, existing data sets, such as the ones from
TCGA, can now be explored with specialized pipelines and new hypotheses. Ongoing projects
headed by Leroy Hood’s Institute for Systems Biology (ISB), in collaboration with the NCI, facilitate
access to TCGA data through implementation of an interactive cloud system (ISB Cancer Genomics
Cloud). These cloud-based improvements mitigate the unwieldiness of big data and streamline the
TCGA database for customizable analyses. We can potentially gain more robust insights into cancer
via enhanced access to existing data sets.
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Thirdly, there is a possibility that the volume of information we can now acquire from
patients has exceeded the limits of human computation and assessment. “Cognitive computing”,
aided by machine-learning algorithms (e.g. IBM Watson), incorporates large quantities of clinical data
into the contexts of therapies, available trials, and treatment sequences – far beyond the capacity of
human processing. It is not unreasonable to imagine that in the not-so-distant future, machine
learning will use many different forms of NGS data to direct clinical decisions.
Fourthly, genomic information attained from FNAs or core biopsies may reflect geographic
biases, as some regions of the tumor are difficult to radiographically visualize and sample. This is a
topic that is of special interest, because it involves a branch of medicine that has recently emerged as
its own specialty. Interventional radiology (IR), previously a fellowship after a diagnostic radiology
residency, is now an independent training program for minimally invasive techniques/treatments and
image-guided procedures. IR physicians use various imaging modalities, including CT, MRI, and
ultrasound, for their biopsies – and correlative studies in IR can reveal associations between certain
cancer types and the efficacy of different imaging approaches. For instance, malignant tissues may
differentially take up fluorodeoxyglucose, causing tumors of a certain subtype to be more accurately
visualized with PET/CT for biopsy guidance. Research in IR can distinguish tumor characteristics to
select the imaging modalities that produce the most representative biopsy sections.

With these future directions in mind, I end on a hopeful note that our ever-broadening innovations in genomic technology
and medicine will help us address existing challenges in cancer treatment.
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